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A B S T R A C T
Background
Dementia assessment often involves initial screening, using a brief tool, followed by more detailed assessment where required. The
AD-8 is a short questionnaire, completed by a suitable ’informant’ who knows the person well. AD-8 is designed to assess change in
functional performance secondary to cognitive change.
Objectives
To determine the diagnostic accuracy of the informant-based AD-8 questionnaire, in detection of all-cause (undifferentiated) dementia
in adults. Where data were available, we described the following: the diagnostic accuracy of the AD-8 at various predefined threshold
scores; the diagnostic accuracy of the AD-8 for each healthcare setting and the effects of heterogeneity on the reported diagnostic
accuracy of the AD-8.
Search methods
We searched the following sources on 27 May 2014, with an update to 7 June 2018: ALOIS (Cochrane Dementia and Cognitive
Improvement Group), MEDLINE (Ovid SP), Embase (Ovid SP), PsycINFO (Ovid SP), BIOSIS Previews (Thomson Reuters Web
of Science), Web of Science Core Collection (includes Conference Proceedings Citation Index) (Thomson Reuters Web of Science),
CINAHL (EBSCOhost) and LILACS (BIREME). We checked reference lists of relevant studies and reviews, used searches of known
relevant studies in PubMed to track related articles, and contacted research groups conducting work on the AD-8 to try to find additional
studies. We developed a sensitive search strategy and used standardised database subject headings as appropriate. Foreign language
publications were translated.
Selection criteria
We selected those studies which included the AD-8 to assess for the presence of dementia and where dementia diagnosis was confirmed
with clinical assessment. We only included those studies where the AD-8 was used as an informant assessment. We made no exclusions
in relation to healthcare setting, language of AD-8 or the AD-8 score used to define a ’test positive’ case.
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Data collection and analysis
We screened all titles generated by electronic database searches, and reviewed abstracts of potentially relevant studies. Two independent
assessors checked full papers for eligibility and extracted data. We extracted data into two-by-two tables to allow calculation of accuracy
metrics for individual studies. We then created summary estimates of sensitivity, specificity and likelihood ratios using the bivariate
approach and plotting results in receiver operating characteristic (ROC) space. We determined quality assessment (risk of bias and
applicability) using the QUADAS-2 tool.
Main results
From 36 papers describing AD-8 test accuracy, we included 10 papers. We utilised data from nine papers with 4045 individuals, 1107
of whom (27%) had a clinical diagnosis of dementia. Pooled analysis of seven studies, using an AD-8 informant cut-off score of two,
indicated that sensitivity was 0.92 (95% confidence interval (CI) 0.86 to 0.96); specificity was 0.64 (95% CI 0.39 to 0.82); the positive
likelihood ratio was 2.53 (95% CI 1.38 to 4.64); and the negative likelihood ratio was 0.12 (95% CI 0.07 to 0.21). Pooled analysis of
five studies, using an AD-8 informant cut-off score of three, indicated that sensitivity was 0.91 (95% CI 0.80 to 0.96); specificity was
0.76 (95% CI 0.57 to 0.89); the positive likelihood ratio was 3.86 (95% CI 2.03 to 7.34); and the negative likelihood ratio was 0.12
(95% CI 0.06 to 0.24).
Four studies were conducted in community settings; four were in secondary care (one in the acute hospital); and one study was in
primary care. The AD-8 has a higher relative sensitivity (1.11, 95% CI 1.02 to 1.21), but lower relative specificity (0.51, 95% CI 0.23
to 1.09) in secondary care compared to community care settings.
There was heterogeneity across the included studies. Dementia prevalence rate varied from 12% to 90% of included participants. The
tool was also used in various different languages. Among all the included studies there was evidence of risk of bias. Issues included the
selection of participants, conduct of index test, and flow of assessment procedures.
Authors’ conclusions
The high sensitivity of the AD-8 suggests it can be used to identify adults who may benefit from further specialist assessment and
diagnosis, but is not a diagnostic test in itself. This pattern of high sensitivity and lower specificity is often suited to a screening test.
Test accuracy varies by setting, however data in primary care and acute hospital settings are limited. This review identified significant
heterogeneity and risk of bias, which may affect the validity of its summary findings.
P L A I N L A N G U A G E S U M M A R Y
How accurate is the AD-8 informant questionnaire for diagnosing dementia in all healthcare settings?
Why is recognising dementia important?
Many people are living with dementia but have never had the condition diagnosed. Not recognising dementia when it is present (a
false negative result) may deny people access to social support, medications, and financial assistance. It also prevents the individual and
their family from planning for the future. However, incorrectly diagnosing dementia when it is not present (a false positive result) can
cause distress or fear and lead to additional investigations which can waste resources.
What is the aim of the review?
The aim of this Cochrane Review was to find out how accurate the AD-8 informant questionnaire is for detecting dementia in all
healthcare settings. The researchers included 10 studies to answer this question, nine of which reported numerical information that
could be used.
What was studied in the review?
The AD-8 questionnaire includes eight ‘yes or no’ questions, to be answered by someone who knows the person under investigation;
for example, a relative, carer or close friend (sometimes described as an informant). The questions ask about whether the informant
has noticed a change in the individual’s memory and thinking abilities over the past years. A point is given for every item where they
think the person’s abilities have changed. Higher scores occur when more changes are noted by the informant. The AD-8 would not
usually be used to make a final diagnosis of dementia, but it may help identify those who require further assessment.
What are the main results of the review?
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The review included data from nine relevant studies, with a total of 4045 participants.
Seven of the studies used a score of two or more to indicate dementia. A score of two or more is the cut-off recommended for the AD-
8. The results of these studies indicate that, in theory, if the AD-8 were to be used to diagnose dementia in a group of 1000 people
across all healthcare settings, of whom 280 (28%) have dementia, an estimated 517 would have an AD-8 result indicating dementia is
present and of these 259 (50%) will not have dementia. Of the 483 people with a result indicating that dementia is not present, 22
(5%) would be incorrectly classified as not having dementia
It is possible that the AD-8 may work differently in different settings, for example in hospital or General practice. In secondary care,
the AD-8 produces more false positive results, but fewer false negative results, than when it is used in community settings. We could
not directly compare the performance of the AD-8 in primary care as there was only one study from this setting.
How reliable are the results of the studies in this review?
In the included studies, the diagnosis of dementia was made by assessing all patients with a detailed clinical assessment. (In these
studies, detailed clinical assessment was the gold standard we compared the AD-8 to.) This is likely to have been a reliable method for
deciding whether patients really had dementia. However, there were some problems with how the studies were conducted. This may
have resulted in the AD-8 appearing more accurate than it really is. The numbers described are an average across studies in the review.
However, as estimates from individual studies varied we cannot be sure that the AD-8 will always produce these results.
Who do the results of this review apply to?
Studies included in the review were conducted in Brazil, China, Japan, Singapore, Taiwan, the UK and USA. Studies included those
attending primary and secondary care services, and populations of older adults living in the community. Five studies used the English-
language version of the AD-8. The percentage of people with a final diagnosis of dementia was between 12% and 90% (an average of
38%).
What are the implications of this review?
The studies included in this review suggest the AD-8 can identify adults who may have a diagnosis of dementia, who would benefit
from specialist assessment and diagnosis. If the AD-8 was used alone to diagnose dementia, the chance of wrongly diagnosing someone
with dementia when they do not actually have it is high (50% of those whose AD-8 score suggests they have dementia). This makes
the AD-8 an unsuitable single diagnostic test as it would potentially create anxiety and distress. The chance of missing a diagnosis of
dementia is much lower (5% of those whose AD-8 score suggests they do not have dementia when they actually have it). This group
will miss out on opportunities to plan their future care and would not be eligible to be assessed for treatment with medicines. These
findings should be considered when deciding whether or not to use the AD-8 to test for dementia.
How up-to-date is this review?
The review authors searched for and used studies published up to June 2018.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Study ID Country Subjects (n) Age (Years) (Mean, SD) AD-8 language Cut-off scores reported Reference standard
Chan 2016 Singa-
pore
309 Malay 3 Dementia
(CDR and DSM-IV)
Chio 2017 Taiwan 153 76.9
(8.6)
Unclear 1, 2, 3, 4 Early cognit ive impairment
(CDR)
Correia 2011 Brazil 109 Portuguese 2, 3 Dementia
(DSM-IV)
Galvin 2006 US 255 73.3
(11.3)
English 2, 3 Various criteria for dementia
Galvin 2007 US 325 76.8
(8.9)
English 1, 2, 3 Dementia
(CDR)
Jackson
2016
UK 125 84.4 English 3, 7 Pre-delirium dementia
(DSM-IV)
Larner 2015 UK 212 Median 64.5
(IQR 12.7)
English 2 Dementia
(DSM-IV)
Meguro 2015 Japan 572 Japanese 2 Dementia
(CDR)
Razavi 2014 US 186 77.8
(8.2)
English 2 Various criteria for dementia
Yang 2016 China 2063 79.5 (7.6) Unclear 2 Dementia
(NIA-AA criteria)
CDR: Clinical Dementia Rating scale
DSM-IV: Diagnost ic and Stat ist ical Manual of Mental Disorders, Fourth Edit ion
NIA-AA: National Inst itute on Aging and Alzheimer’s Associat ion
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B A C K G R O U N D
Dementia is a substantial and growing public health concern
(Livingston 2017; Prince 2013). As an example, depending on case
definition employed, contemporary estimates of dementia preva-
lence in the United States are in the range 2.5 to 4.5 million in-
dividuals (up to 1.6% of the population; 6.5% of those aged over
65) (Hebert 2013). Changes in population demographics will be
accompanied by increases in global dementia incidence and preva-
lence (Ferri 2005). Although the magnitude of the increase in
prevalent dementia may have been overestimated in previous pre-
diction models (Matthews 2013), there is no doubt that absolute
numbers of older adults with dementia will increase substantially
in the short- to medium-term future (Ferri 2005).
A key element of effective management in dementia is a firm diag-
nosis. Recent guidelines place emphasis on early diagnosis to facil-
itate improved management and enable informed discussions and
planning with patients and carers. The benefits of screening for
cognitive decline are debated (Brunet 2012); however, in certain
healthcare systems, screening or case-finding has already been in-
troduced for certain groups, e.g. unscheduled hospital admissions
of older adults (Burn 2018; Robinson 2015).
Given the projected global increase in dementia prevalence, there
is potential tension between the clinical requirements for robust
diagnosis at the individual patient level and the need for equitable,
easy access to diagnosis at a population level. The ideal would be
expert, multidisciplinary assessment informed by various supple-
mentary investigations (neuropsychology; neuroimaging or other
biomarkers). This approach is only really feasible in a specialist
memory service and is not suited to population screening or case-
finding at scale.
In practice, a two-stage process is often employed. This involves
initial ’triage’ assessments, suitable for use by non-specialists, to
select those who require second-stage, further detailed assessment
(Boustani 2003).
Various tools for initial cognitive screening have been described
(Brodaty 2002; Folstein 1975). Regardless of the methods em-
ployed, there is scope for improvement, with observational work
suggesting that many people with dementia are not diagnosed
(Bradford 2009; Chodosh 2004; Lang 2017; Valcour 2000).
Screening assessment often takes the form of brief, direct cognitive
testing. Such an approach will only provide a ’snapshot’ of cogni-
tive function. However, a defining feature of dementia is cogni-
tive or neuropsychological change over time. People with cognitive
problems themselvesmay struggle tomake an objective assessment
of personal change and so an attractive approach is to question
collateral sources with sufficient knowledge of the person. These
informant-based interviews aim to assess change in function ret-
rospectively.
An instrument prevalent in research and clinical practice, par-
ticularly in North America, is the AD-8 informant question-
naire (Galvin 2005). The authors of the tool describe it as the
AD-8, without further definition of the acronym (Galvin 2005).
However, it is also described as the Ascertaining Dementia inter-
view (Correia 2011), Ascertain Dementia 8 questionnaire (Chen
2018) and the Ascertain Dementia 8-item Informant Question-
naire (Chen 2017) in the literature. This screening/triage tool will
be the focus of this review.
A number of properties can be described for a clinical assessment
(reliability, responsiveness, feasibility). For our purposes, the test
property of greatest interest is diagnostic test accuracy (DTA) (
Cordell 2013).
Although we describe test accuracy of the AD-8 for dementia diag-
nosis, the AD-8 is not suitable for establishing a clinical diagnosis
of dementia when used in isolation. The AD-8 can be described
in different ways dependent on the setting and purpose of testing.
Target condition being diagnosed
The target condition for this DTA review is all-cause dementia
(clinical diagnosis).
Dementia is a syndrome characterised by cognitive or neuropsy-
chological decline sufficient to interfere with usual functioning.
The neurodegeneration and clinical manifestations of dementia
are progressive and at present there is no ’cure’, although numer-
ous interventions to slow or arrest cognitive decline have been de-
scribed, including pharmacological (Birks 2018; McShane 2006),
and non-pharmacological (Bahar-Fuchs 2013).
Dementia remains a clinical diagnosis, based on history from the
person and suitable collateral sources and direct examination, in-
cluding cognitive assessment. There is no universally-accepted,
ante-mortem, gold-standard diagnostic strategy. We have chosen
expert clinical diagnosis as our gold standard (reference standard)
for describing AD-8 test properties, as we believe this is most in
keeping with current diagnostic criteria and best practice.
Dementia diagnosis can be made according to various interna-
tionally-accepted diagnostic criteria, with exemplars being the
World Health Organization, International Classification of Dis-
eases (ICD) (ICD-10), and the American Psychiatric Association
Diagnostic and Statistical Manual of Mental Disorders (DSM)
(DSM-IV) for all-cause dementia and subtypes (Appendix 1).
The label of dementia encompasses varying pathologies, of which
Alzheimer’s disease is the most common. Diagnostic criteria are
available for specific dementia subtypes, e.g. NINCDS-ADRDA
criteria for Alzheimer’s dementia (McKhann 1984; McKhann
2011);McKeith criteria for Lewy body dementia (McKeith 2005);
Lund criteria for frontotemporal dementias (McKhann 2001); and
theNINDS-AIREN criteria for vascular dementia (Román 1993).
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Index test(s)
Our index test was the AD-8 informant questionnaire (Galvin
2005) (Appendix 2; Appendix 3).
First published in 2005, the AD-8 is a screening tool which has
been used to distinguish individuals with dementia or mild cog-
nitive impairment (MCI) from those with normal cognitive func-
tion. It is designed to be administered to a relevant proxy, usually a
relative or carer, in questionnaire form. The AD-8 is a brief screen-
ing tool.With only eight questions, it takes less than threeminutes
to complete and was developed to replace other lengthy informant
questionnaires (Galvin 2006). The AD-8 was originally developed
for administration in the English language but has been repro-
duced in other languages including Brazilian Portuguese (Correia
2011), Taiwanese (Yang 2011), and Korean (Ryu 2009).
TheAD-8 items cover domains of judgement, hobby/activity level,
repetitive conversations, learning ability, memory in relation to
date/appointments, finances and daily thought processes. Infor-
mants indicate presence of change ’over several years’ using re-
sponses of ‘Yes, a change’, ‘No, no change’ or ‘NA, don’t know’.
Each ’yes’ answer is scored one point. Final scores range from zero,
where no change has been noticed by the informant, to eight,
where change has been noted across all domains. The commonly
employed threshold score for the AD-8 to differentiate cognitive
from no cognitive impairment is greater than or equal to two out
of eight (i.e. a ’yes’ response for two or more items) (Galvin 2005).
The AD-8 has a number of features that potentially make it attrac-
tive for clinical and research use. The questions used have an im-
mediacy and relevance that is likely to appeal to users. Assessment
and (informant) scoring is brief, and as the scale is not typically
interviewer-administered it requires minimal training in applica-
tion and scoring. There are data to suggest that, compared to stan-
dard direct assessments, informant interviews may be less prone
to bias from cultural norms and previous level of education (Jorm
2004). As diagnostic criteria for dementia make explicit reference
to documenting decline and involving collateral informants, the
potential utility of an informant interview tool such as the AD-8
is clear.
Clinical pathway
Dementia develops over a trajectory of several years, and tests may
be performed at different stages in the dementia pathway. In this
review we considered any use of the AD-8 as an initial assessment
for cognitive decline, and did not limit our inclusion criteria to a
particular healthcare setting. We have operationalised the various
settings where the AD-8 may be used as secondary care, primary
care, and community.
In secondary-care settings, patients will have been referred for ex-
pert input but not exclusively due to memory complaints. Cog-
nitive testing in secondary care involves two main groups: oppor-
tunistic screening of adults presenting as unscheduled admissions
to hospitals, and those people referred to specific services for de-
mentia, memory or psychiatry of older age. Both populations will
have a high prevalence of cognitive disorders and mimics. In-hos-
pital estimates of dementia prevalence vary from 15% to 42%,
dependent on methodology used (Jackson 2017). Secondary-care
patients are more likely to have had a degree of prior cognitive
assessment than those in other settings, although we recognise that
cognitive screening prior to referral to specialist services is neither
consistent nor guaranteed (Menon 2011).
The prevalence of dementia in primary care is estimated to be
1.4% (Donegan 2017), and it has been projected that most Gen-
eral practitioners could expect one to two new cases each year, per
physician (Iliffe 2009). However, cognitive testing in the General
practice/primary-care setting is likely to be conducted in response
to an individual person self-presenting because of subjective mem-
ory complaints, a common finding in older adults, estimated to
be reported by 25% to 50% of those aged 65 years and over (Iliffe
2010). Using the AD-8 in this setting could be described as ’triage’
or ’case finding’ to determine individuals with objective concerns
requiring further investigation.
In the community setting, the cohort is largely unselected.The
estimated prevalence of dementia in those aged 65 years and over
is 6.5% (Matthews 2013) and this age group accounts for ~18% of
the population (Office for National Statistics 2018). This means
dementia prevalence will be low compared to other settings. In
the community setting, use of the AD-8 as a cognitive testing
approach may be described as ’population screening’.
Most studies of test accuracy compare the test against contempo-
raneous reference standards (in this case, clinical dementia diag-
nosis). An alternative is to describe the test properties for detection
of early, ’pre-clinical’ problems that are formally diagnosed during
prospective, longitudinal follow-up. This delayed verification ap-
proach is commonly employed in studies describing properties of
dementia biomarkers, but may have utility for other test strategies
such as informant interview.
Rationale
There is no consensus on the optimal initial assessment for demen-
tia, and choice is currently dictated by experience with a particular
instrument, time constraints and training. A better understanding
of the diagnostic properties of various strategies would allow for an
informed approach to testing. Critical evaluation of the evidence
base for screening tests or other diagnostic markers is of major im-
portance. Without a robust synthesis of the available information
there is the risk that future research, clinical practice and policy
will be built on erroneous assumptions about diagnostic validity.
The AD-8 is commonly used in practice and research; it is used
internationally and is one of only a few validated informant-based
screening/diagnostic tools. A body of literature describing the test
accuracy of the AD-8 in different settings is available, although
some of these studies have been modest in size. Thus, systematic
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review and, if possible, meta-analysis of the diagnostic properties
of the AD-8 is warranted.
This review forms part of a body of work describing the diagnostic
properties of commonly-used dementia tools (Appendix 4). At
present we are conducting single-test reviews and meta-analyses.
However, the intention is then to collate these data and perform
an overview, to enable comparison of various test strategies.
O B J E C T I V E S
To determine the diagnostic accuracy of the informant-based AD-
8 questionnaire, in detection of all-cause (undifferentiated) de-
mentia in adults.
Secondary objectives
Where data were available, we described the following.
1. The diagnostic accuracy of the AD-8 at various predefined
threshold scores (one, two, three). These thresholds have been
chosen to represent the range of cut-off scores that are commonly
used in practice and research; we have been inclusive in our
choice of cut-off score to maximise available data for review.
2. The diagnostic accuracy of the AD-8 for each healthcare
setting (community; primary care; secondary care).
3. The effects of heterogeneity on the reported diagnostic
accuracy of the AD-8. Potential sources of heterogeneity that we
intended to explore were: case mix of cohort; method of
dementia diagnosis; method (language) of AD-8 assessment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We anticipated that the majority of the studies would be of AD-
8 test properties compared against a contemporaneous clinical di-
agnosis of dementia in secondary-care settings. We included test
studies performed in other healthcare settings, and classified set-
tings as secondary care, primary care, or community.
Case-control studies are known to potentially overestimate prop-
erties of a test and we did not include such studies in the review
(Davis 2013).
We also did not include case studies or samples with very small
numbers (chosen as 10 participants, for the purposes of this re-
view).
Where settings were mixed, for example, a population study ’en-
riched’ with additional cases from secondary care, we did not con-
sider such studies unless separate data were presented for partic-
ipants from each setting. This design can be affected by similar
biases to a case-control design.
Participants
All adults (aged over 18 years) were eligible.
We did not predefine exclusion criteria relating to the ’case mix’
of the population studied, but assessed this aspect of the study as
part of our assessment of heterogeneity.
Index tests
Studies must have included (not necessarily exclusively) the AD-
8, used as an informant questionnaire.
The AD-8 has been translated into various languages to enable
international administration. The properties of a translated AD-8
in a cohort of non-English speakers may differ from the properties
of the original English-language questionnaire. We collected data
on the principal language used for AD-8 assessment.
For this review we did not consider other cognitive screening/
assessment tools. Where a paper described the AD-8 with in-study
comparison against another screening tool, we included the AD-8
data only.Where the AD-8 was used in combination with another
cognitive screening tool, we included the AD-8 data only.
Target conditions
We included any clinical diagnosis of all-cause (unspecified) de-
mentia. We did not require a definition of a particular dementia
subtype, although we recorded this information where available.
Reference standards
Our reference standard is clinical diagnosis of dementia.We recog-
nise that clinical diagnosis itself has a degree of variability but this
is not unique to dementia studies and does not invalidate the basic
diagnostic test accuracy (DTA) approach.
The primary analysis for clinical diagnosis included all-cause (un-
specified) dementia, using any recognised diagnostic criteria (for
example, DSM-IV; ICD-10). We included use of the full Clini-
cal Dementia Rating (CDR) Scale (Morris 1993) as an acceptable
method formaking a dementia diagnosis, with aCDRscore greater
than or equal to one for a clinical diagnosis of dementia. Demen-
tia diagnosis may have specified a pathological subtype and we
included all common dementia subtypes, e.g. NINCDS-ADRDA
(Alzheimer’s disease), Lund-Manchester (frontotemporal demen-
tia), McKeith (Dementia with Lewy bodies), NINCDS-AIREN
(vascular dementia) (McKeith 2005; McKhann 1984; McKhann
2001; Román 1993).We did not define preferred diagnostic crite-
ria for rarer forms of dementia (e.g. alcohol-related; HIV-related;
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prion disease-related). These were considered under our rubric of
’all-cause’ dementia, and not considered separately.
The label ’dementia’ can span a range of disease severities, from
mild disease to ’end stage’. The diagnostic properties of a tool will
vary depending on disease stage, for example, true positives are
more likely when disease is advanced and diagnosis is clear. For
our primary analysis we included any dementia diagnosis, at any
stage of disease.
Clinicians may use imaging, pathology or other data to aid diag-
nosis; however, we did not include diagnosis based only on these
data without corresponding clinical assessment. We recognise that
different iterations of diagnostic criteria may not be directly com-
parable, and that diagnosis may vary with the degree or manner
in which the criteria have been operationalised (e.g. individual
clinician versus algorithm versus consensus determination). We
collected data on method and application of dementia diagnosis
for each study and explored the validity of the dementia diagnosis
as part of our ’Risk of Bias’ assessment. We did not accept use
of other (brief ) direct performance tests in isolation as a basis for
diagnosis.
We recognise that dementia diagnosis often comprises a degree of
informant assessment. Thus there is potential for incorporation
bias. We explored the potential effects of this bias through our
’Risk of bias’ assessment.
Search methods for identification of studies
We used a variety of information sources to ensure all relevant
studies were included. We devised terms for electronic database
searching in conjunction with the team at the Cochrane Dementia
and Cognitive Improvement Group. As this AD-8 review forms
part of a suite of reviews looking at informant scales, we have
created a comprehensive search strategy designed to pick up all
cognitive assessment scales (Quinn 2014); we complemented this
generic search with searches specific to AD-8 terminology.
Electronic searches
We searched the specialised register of the Cochrane Dementia
and Cognitive Improvement Group, ALOIS (which includes both
intervention and diagnostic accuracy studies), MEDLINE (Ovid
SP), Embase (Ovid SP), BIOSIS (ISI Web of Science), Web of
Science Core Collection (ISI Web of Science), PsycINFO (Ovid
SP), CINAHL (EBSCOhost) and LILACS (Bireme).We designed
similarly-structured search strategies and used search terms appro-
priate to each database. We used MeSH words and other con-
trolled vocabulary where appropriate.
We also searched sources specific to diagnostic accuracy or system-
atic review:
·MEDIONdatabase (Meta-analyses vanDiagnostischOnderzoek
www.mediondatabase.nl);
· DARE (Database of Abstracts of Reviews of Effects) and HTA
Database (Health Technology Assessments Database), both The
Cochrane Library;
· ARIF database (Aggressive Research Intelligence Facility;
www.arif.bham.ac.uk).
See Appendix 5 and Appendix 6 for the search strategies run.
We did not apply language or date restrictions to the electronic
searches, nor did we apply restrictions regarding publication status
when assessing records for potential inclusion, including abstracts,
conference proceedings and unpublished data. We used transla-
tion services where necessary (see: Acknowledgements), and used
a translation proforma for data extraction (Appendix 7).
The Cochrane Dementia and Cognitive Impairment Group In-
formation Specialist (ANS) ran the initial searches.The most re-
cent search for this review was performed on 7 June 2018.
Searching other resources
Grey literature and proceedings: we searched our chosen electronic
databases and included relevant assessments of conference pro-
ceedings.Where possible we accessed theses or PhD abstracts from
institutions known to be involved in prospective dementia studies.
Handsearching: we did not perform handsearching as there is little
published evidence of the benefits of handsearching for diagnostic
studies (Glanville 2010).
Reference lists: we checked the reference lists of all relevant studies
and reviews in the field for further possible titles, and repeated the
process until no new titles were found (Greenhalgh 2005).
Correspondence: We contacted research groups who have pub-
lished or are conducting work on AD-8 for dementia diagnosis,
informed by results of initial search (see: Acknowledgements).
We used relevant studies in PubMed to search for additional stud-
ies using the ’related article’ feature. We examined key studies in
citation databases, such as Science Citation Index and Scopus, to
ascertain details of any further relevant studies.
Data collection and analysis
Selection of studies
One review author (ANS) screened all titles generated by initial
electronic database searches for relevance. The initial search was
a sensitive, generic search, designed to include all potential de-
mentia screening tools. Two review authors (KH, CG) then in-
dependently screened all remaining titles for relevance. The two
review authors inspected abstracts of selected titles and selected
all potentially eligible studies for full-text review. They indepen-
dently assessed full manuscripts against the inclusion criteria, and
resolved disagreements by discussion or by involving an arbitrator
where necessary.
Where a study included useable data but did not present these
in the published manuscript, we contacted the authors directly to
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request further information. If the same data were presented in
more than one paper we included the primary paper only.
We have detailed the study selection process in a PRISMA flow
diagram.
Data extraction and management
We extracted data to a study-specific pro forma that included clin-
ical/demographic details of the participants; details of setting; de-
tails of AD-8 administration and details of the dementia diagnosis
process.
Where AD-8 data were presented for differing threshold scores,
we extracted data for each threshold and collated these separately.
We extracted test accuracy data to a standard two-by-two table.
Two review authors (KH, CG), blinded to study identifiers, per-
formed data extraction independently. They resolved disagree-
ments by discussion, with the use of an arbitrator if necessary. As
a further check of validity of search and data extraction, a third
reviewer (SA) assessed all titles and papers from the most recent
updated literature search.
For each included paper, we detailed the flowof participants (num-
bers recruited, included, assessed) in a flow diagram.
Assessment of methodological quality
We assessed the methodological quality of each study using the
QUADAS-2 tool (www.bris.ac.uk/quadas/quadas-2) (Appendix
8). This tool incorporates domains specific to participant selec-
tion; index test; reference standard; and participant flow. Each
domain is assessed for risk of bias and the first three domains
are also assessed for applicability. Certain key areas important for
quality assessment are participant selection, blinding, and missing
data. Following a group meeting of review authors, we created
guidance for the application of QUADAS-2 to dementia screen-
ing assessments, specifically developing anchoring statements for
QUADAS-based assessment that are suited to dementia test ac-
curacy studies. This QUADAS-2 guidance was created through a
multidisciplinary working group and has been extensively piloted.
The process and resulting statements for assessment are described
in Appendix 9.
We did not useQUADAS-2 data to form a summary quality score;
we produced a narrative summary describing numbers of studies
for which we found high/low/unclear risk of bias, or concerns
regarding applicability with corresponding tabular and graphical
displays.
Paired independent raters (KH, CG), blinded to each other’s
scores, performed both assessments. They resolved disagreements
by further review and discussion, with recourse to a third-party
arbitrator where necessary. A third reviewer assessed all titles se-
lected from the most recent literature search.
Statistical analysis and data synthesis
We were interested in the test accuracy of the AD-8 for the di-
chotomous variable ’dementia’/’no dementia’. Thus, we applied
the current Cochrane DTA framework for analysis of a single test.
We extracted data from included papers to allow creation of a
standard two-by-two data table showing dichotomised AD-8 test
results (AD-8 positive or AD-8 negative), cross-classified with bi-
nary reference standard (dementia or no dementia).
We used Review Manager 5 software (RevMan 2012) to calculate
sensitivity, specificity and 95% confidence intervals (CIs) from
the two-by-two tables abstracted from the included studies. We
used a threshold score of two or more on the AD-8 for primary
analyses. If data at other thresholds were presented, we examined
these in separate analyses (we were able to describe accuracy at cut-
off scores of one, two, three, and seven). We presented individual
study results graphically by plotting estimates of sensitivities and
specificities as forest plots.
To allow for summary analysis, we used SAS release 9.4, in addi-
tion to Review Manager 5. Using the bivariate approach we de-
scribed metrics of pooled sensitivity, specificity, positive and neg-
ative likelihood ratios, all with corresponding 95% confidence in-
tervals. We plotted summary data in receiver operating character-
istic (ROC) space, including 95% confidence regions. Where we
were interested in comparative accuracy and where data allowed,
for example differential accuracy by setting, we plotted summary
accuracy data for each variable in shared ROC space and described
relative sensitivity and specificity of one factor to the other.
We suspected papers would use the classical cross-sectional test
accuracy study design. An alternative is the ’delayed verification’
study design, i.e. where the AD-8 is performed at baseline and
those without disease are prospectively followed up for develop-
ment of incident dementia. No included studies took this ap-
proach, but if they had, we planned to use baseline (contempora-
neous testing) data for our primary analysis.
Investigations of heterogeneity
Heterogeneity is expected in DTA reviews, and ’traditional’ mea-
sures of heterogeneity used in meta-analysis are not appropriate to
DTA reviews.
The properties of a tool describe behaviour of the instrument un-
der particular circumstances. We included all AD-8 studies in nar-
rative review. We prespecified particular areas of potential hetero-
geneity, as follows.
AD-8 threshold score
We included data from all AD-8 threshold scores described in the
included studies. Where data allowed, we collated scores at each
cut-off score of test positivity, using meta-analytical techniques to
create summary estimates of sensitivity and specificity.
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Healthcare setting
We suspected that healthcare setting would impact on properties
of the test. Our primary analysis was across all settings; where
data allowed, we performed sensitivity analysis comparing hospi-
tal-based (secondary care) settings and primary care or community
settings.
Case mix
In the first instance we explored age, taking age over 65 years as
a reference point. We anticipated that the majority of included
participants in eligible studies would be aged over 65 years. The
AD-8 may have different properties in younger cohorts and so we
looked at age ranges within studies. We planned to grade studies
with greater than 20% of included participants younger than 65
years as potentially unrepresentative. Where studies offered test
accuracy at different age ranges, we chose the range that best rep-
resented our primary population of interest, namely older adults
(aged over 65 years).
We anticipated that most studies would be of unselected adults,
however we included studies that limited inclusion to a specific
population, for example stroke survivors. For studies of selected
populations, we assessed the validity of inclusion in a summary
analysis with other included studies on a case-by-case basis.
We suspected that the majority of studies would focus on all-cause
(undifferentiated) dementia or Alzheimer’s disease, but included
any dementia pathology in the review. We assessed generalisability
according to age, comorbidity and dementia pathology, as part
of our ’Risk of Bias’ assessment. If data allowed, we planned to
run sensitivity analyses removing studies with unrepresentative
populations.
Criteria used to reach dementia diagnosis
We recorded the classification used (for example, DSM-IV;
ICD-10) and the methodology used to reach dementia diagno-
sis (for example, individual assessment; group (consensus) assess-
ment). We assessed the ’quality’ of diagnosis at study level using
the QUADAS-2 tool. If data allowed, we planned subgroup anal-
yses comparing differing approaches to diagnosis.
Technical features of the testing strategy
Our focus was on language of assessment. We classified this as
either English language or non-English-language tests. We per-
formed subgroup analyses comparing the English-language AD-8
versus non-English-language AD-8.
Sensitivity analyses
Where appropriate (i.e. if not already explored in our analyses of
heterogeneity), and as data allowed, we explored the sensitivity of
any summary accuracy estimates to other methodological aspects
of the included studies.We performed a sensitivity analysis exclud-
ing a paper with a disease-specific patient group (those with delir-
ium). We also performed a post-hoc sensitivity analysis excluding
a paper whose test accuracy estimates were based on a more inclu-
sive definition of dementia than was used in the other papers. We
had planned to perform sensitivity analyses based on key aspects
that could indicate risk of bias, such as nature of blinding and loss
to follow-up, guided by the anchoring statements developed in
our QUADAS-2 exercise. Due to the modest number of included
studies, and the lack of papers deemed to have low risk of bias on
all domains, we were unable to perform these analyses.
Assessment of reporting bias
We did not investigate reporting bias because of current uncer-
tainty about how it operates in test accuracy studies, and about the
interpretation of existing analytical tools such as the funnel plot
(van Enst 2014).
R E S U L T S
Results of the search
Our search resulted in 3661 records, from which we identified 36
full-text papers for eligibility. We included 10 studies, with a total
of 4309 participants (Summary of findings 1).
We identified two studies which required translation (Munoz
2010; Pardo 2013). We contacted three authors to provide addi-
tional data, and one author provided this for incorporation in the
review (see: Acknowledgements).
We excluded 26 papers. The most frequent reasons for exclusion
were: case-control data (n = 10); unsuitable reference standard (n
= 7) and repeat data set (n = 2) (see Characteristics of excluded
studies). We excluded one study following repeated review and
consultation with the review group Editor (Malmstrom 2009).
The study subgroup, which could have been eligible, did not in-
clude any participants with a cognitive diagnosis that was com-
patible with our prespecified criteria for dementia (clinical diag-
nosis using a recognised clinical classification system and/or Clin-
ical Dementia Rating (CDR) Scale score of one or more) As our
review focuses on dementia, we chose to exclude this study. For a
PRISMA flow diagram depiciting study selection, see Figure 1.
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Figure 1. Study flow diagram.
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Methodological quality of included studies
Wedescribed the risk of bias and applicability using theQUADAS-
2 methodology (Appendix 8); our anchoring statements for the
AD-8 are summarised in Appendix 9.
We did not rate any included study as being at low risk of bias
for all the categories of QUADAS-2. For all domains there were
papers where risk of bias was high or where reporting was insuf-
ficient, which necessitated an assessment of unclear risk of bias.
There were particular issues around inappropriate exclusions of
participants (for example, exclusion those who had dementia) and
around patient flow (for example, substantial dropouts due to in-
ability to complete test). We had fewer concerns around applica-
bility. See: Figure 2.
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Figure 2. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study
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Findings
We have described the individual included studies in
Characteristics of included studies and Table 1. We have also
presented tabulated data for test accuracy by AD-8 threshold
(Summary of findings 2), and by setting and language of admin-
istration (Summary of findings 3).
The total number of participants across the studies was 4309
(range: 109 to 2063). One study (n = 153 participants) identi-
fied cases of dementia (those with a CDR score of one or more),
but did not provide the test accuracy data specific to this (Chio
2017). The focus of the paper was on identifying early cognitive
impairment and so, while the study was eligible for inclusion in
review, we could not include its data in the quantitative synthesis.
We performed quantitative synthesis for nine studies, including
a total of 4045 participants of whom 1107 (27%) had a clinical
dementia diagnosis. This excludes 14 participants from Galvin
2006, who were missing a clinical diagnosis; one participant from
Galvin 2007, who had no reference standard data; and 48 partic-
ipants from Jackson 2016, plus 48 participants from Yang 2016,
who were lacking complete follow-up assessment data. Dementia
prevalence in the included studies varied from 12% to 90%.
Nine of the ten studies are included in the quantitative synthesis.
Seven studies used a cut-off score of two to differentiate dementia
from no dementia, and five reported data using a cut-off of three.
We did not consider it was appropriate to combine data using
different cut-off scores of test positivity. The cut-off scores used
to define a ’positive’ AD-8 included scores of one, two, three, and
seven.
The included studies are international, including datasets from
seven countries (Brazil, China, Japan, Singapore, Taiwan, the UK,
the USA). Four different language versions of the AD-8 were used,
although in two papers it was not clear if the authors had used a
translated version.
Using a cut-off score of two, there was a spread of sensitivity and
specificity (sensitivity range: 73% to 99%; specificity range: 11%
to 93%). Using a cut-off score of three, there was a spread of sen-
sitivity and specificity (sensitivity range: 75% to 100%; specificity
range: 40% to 91%). Table 1 provides a summary of the test accu-
racy for each study, presenting results at cut-off scores of two and
three where available, ordered by dementia prevalence.
AD-8 using an informant cut-off score of two
Seven studies (n = 3659) reported data using an AD-8 informant
cut-off score of two (Correia 2011; Galvin 2006; Galvin 2007;
Larner 2015; Meguro 2015; Razavi 2014; Yang 2016). Sensitivity
was 0.92 (95% confidence interval (CI) 0.86 to 0.96); specificity
was 0.64 (95% CI 0.39 to 0.82). The overall positive likelihood
ratio was 2.53 (95% CI 1.38 to 4.64) and the negative likelihood
ratio was 0.12 (95% CI 0.07 to 0.21). The summary describing
test accuracy across the included studies in receiver operating char-
acteristic (ROC) space is presented in Figure 3.
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Figure 3. Summary ROC plot of AD-8 informant cut-off score 2. The dark point is a summary point, the
other points individual studies; the broken line represents 95% confidence region.
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AD-8 using an informant cut-off score of three
Five studies (n = 1060) reported data using an AD-8 informant
cut-off score of three (Chan 2016; Correia 2011; Galvin 2006;
Galvin 2007; Jackson 2016). These gave a sensitivity of 0.91 (95%
CI 0.80 to 0.96) and specificity of 0.76 (95% CI 0.57 to 0.89).
The overall positive likelihood ratio was 3.86 (95% CI 2.03 to
7.34) and the negative likelihood ratio was 0.12 (95% CI 0.06 to
0.24). The summary describing test accuracy across the included
studies in ROC space is presented in Figure 4 .
16AD-8 for detection of dementia across a variety of healthcare settings (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 4. Summary ROC plot of AD-8 informant cut-off score 3. The dark point is a summary point, the
other points individual studies; the broken line represents 95% confidence region.
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AD-8 test accuracy at other diagnostic thresholds for
dementia
AD-8 informant cut-off score of one
One study (n = 324) reported data using an AD-8 informant cut-
off score of one (Galvin 2007). This had a sensitivity of 0.90 (95%
CI 0.81 to 0.96) and specificity of 0.68 (95% CI 0.62 to 0.74).
AD-8 informant cut-off score of seven
One study (n = 77) reported data using an AD-8 informant cut-
off score of seven (Jackson 2016). This had a sensitivity of 0.83
(95% CI 0.69 to 0.92) and specificity of 0.90 (95% CI 0.73 to
0.98).
Heterogeneity relating to setting
Primary care
One study (n = 309) was conducted in a primary care setting,
specifically the waiting areas of healthcare centres in Singapore
(Chan 2016). Data were only reported using an AD-8 cut-off
score of three. The sensitivity was 0.91 (95% CI 0.78 to 0.97) and
specificity was 0.91 (95% CI 0.87 to 0.94).
Community
Four studies (n = 2937) were conducted in community settings
(Correia 2011; Galvin 2007; Meguro 2015; Yang 2016).
Data were available at a cut-off score of two for all four studies.
The sensitivity was 0.86 (95% CI 0.78 to 0.92) and specificity
was 0.78 (95% CI 0.57 to 0.90). The overall positive likelihood
ratio was 3.89 (95% CI 1.76 to 8.59) and the negative likelihood
ratio was 0.18 (95% CI 0.10 to 0.31). The dementia prevalence
ranged from 12% to 23%.
Secondary care
Four studies (n = 716) were conducted in secondary care settings.
This included three in outpatient neurology, cognitive function or
memory clinics (Galvin 2006; Larner 2015; Razavi 2014), and one
study of hospitalised individuals with delirium (Jackson 2016).
Data were available for three of the studies at a cut-off score of
two (excluding Jackson 2016, which only reported data using a
cut-off score of three). The sensitivity was 0.96 (95% CI 0.92 to
0.98) and specificity was 0.39 (95% CI 0.16 to 0.69). The overall
positive likelihood ratio was 1.58 (95% CI 0.98 to 2.57) and the
negative likelihood ratio was 0.10 (95% CI 0.03 to 0.33). The
dementia prevalence ranged from 33% to 90%.
Comparing pooled test accuracy between the two settings, the AD-
8 has a higher relative sensitivity (1.11, 95% CI 1.02 to 1.21), but
lower relative specificity (0.51, 95%CI 0.23 to 1.09), in secondary
care compared to community care settings (Figure 5).
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Figure 5. Summary ROC plot of AD-8 informant cut-off score 2 comparing test accuracy in community
versus secondary care settings. Red diamonds represent community studies and black circles those in
secondary care. The dark point is a summary point, the other points individual studies; the broken line
represents 95% confidence region. No confidence region calculable for secondary care due to lack of available
data.
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Other sources of heterogeneity and sensitivity
analyses
Age
We performed a sensitivity analysis removing the study which
included participants with a lowmean or median age (less than 65
years) (Larner 2015). Using a cut-off score of two, test accuracy
was similar after exclusion of this study, with an improvement in
the specficity of the AD-8: sensitivity was 0.91 (95% CI 0.83 to
0.95); specificity was 0.73 (95% CI 0.59 to 0.84); the positive
likelihood ratio was 3.42 (95% CI 2.12 to 5.49); and the negative
likelihood ratio was 0.12 (95% CI 0.07 to 0.23) (Figure 6).
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Figure 6. Summary ROC plot of sensitivity analysis removing low average age. The dark point is a summary
point, the other points individual studies; the broken line represents 95% confidence region.
Disease-specific populations
One study included a disease-specific population, individuals with
a diagnosis of delirium (Jackson 2016).We performed a sensitivity
analysis, removing this study from all the others using a cut-off
score of three. Results showed a lower sensitivity and higher speci-
ficity than the pooled analysis result. Sensitivity was 0.88 (95%
CI 0.78 to 0.94) and specificity was 0.83 (95% CI 0.69 to 0.91).
The overall positive likelihood ratio was 5.04 (95% CI 2.82 to
9.01) and the negative likelihood ratio was 0.15 (95% CI 0.08 to
0.26).
Reference standard dementia diagnostic method
Three studies used the CDR as their reference standard (Chan
2016; Galvin 2007; Meguro 2015); three used the DSM-IV
criteria (Correia 2011; Jackson 2016; Larner 2015); two stud-
ies used various criteria for dementia diagnosis (Galvin 2006;
Razavi 2014); and one used the National Institute on Aging and
Alzheimer’s Association (NIA-AA) criteria (Yang 2016). Quanti-
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tative comparisons based on the diagnostic criteria used were not
possible due to the small numbers of studies using each method.
One study took amore inclusive definition of dementia, including
those with a CDR score of 0.5 in their summary test accuracy
data (Galvin 2007). For the purposes of analysis, we used the total
numbers with a clinical diagnosis of dementia (CDR score greater
than or equal to one), in common with the approach used in all
other studies and theCDR definitions (Morris 1993).We used the
summary sensitivity and specificity data presented in the paper,
however the prevalence of dementia was lower than that quoted
due to our exclusion of those 102 participants scoring 0.5 from
the disease-positive group (54% quoted in study reduced to 23%).
As such, we performed a post-hoc sensitivity analysis to check
the effects of including the data from this study on our summary
estimates at cut-off scores of two and three.
Using a cut-off score of two, removing data from Galvin 2007
resulted in similar sensitivity (0.93, 95% CI 0.86 to 0.97); but
lower specificity (0.56, 95%CI 0.34 to 0.76); a positive likelihood
ratio of 2.10 (95% CI 1.28 to 3.43) and negative likelihood ratio
of 0.12 (95% CI 0.06 to 0.25). Using a cut-off score of three,
removing data from Galvin 2007 resulted in similar sensitivity
(0.92, 95% CI 0.80 to 97); but lower specificity (0.71, 95% CI
0.48 to 0.87), with wider confidence intervals. The overall positive
likelihood ratio was 3.19 (95% CI 1.61 to 6.33) and the negative
likelihood ratio was 0.11 (95% CI 0.04 to 0.28).
Disease subtype
No studies considered a specific dementia subtype to facilitate
sensitivity analysis based on this.
Language of AD-8 administration
The English-language version of the AD-8 was used in five studies
(Galvin 2006; Galvin 2007; Jackson 2016; Larner 2015; Razavi
2014). Three studies named which specific non-English-language
versions were used (Chan 2016; Correia 2011; Meguro 2015).
In two studies the language of AD-8 administration was unclear
(Chio 2017; Yang 2016).
The summary test accuracy of the English-language version, used
at a cut-off score of two (n = 963) was calculated, resulting in
sensitivity of 0.95 (95% CI 0.87 to 0.98); and specificity of 0.59
(95% CI 0.21 to 0.89). The overall positive likelihood ratio was
2.30 (95% CI 0.87 to 6.07) and the negative likelihood ratio was
0.08 (95% CI 0.03 to 0.22). Only three studies using a cut-off
score of three used theEnglish-language version, and thuswe could
not pool the data.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
What is the accuracy of the AD-8 test for the detection of dementia when differing thresholds are used to define AD-8 positive cases?
Population Adults whose informant completed an AD-8 quest ionnaire, with no restrict ions on the case mix of recruited part icipants
Setting Primary care, community and secondary care
Index test AD-8 informant-based quest ionnaire
Reference standard Clinical diagnosis of dementia made using any recognised classif icat ion system
Studies We included cross-sect ional but not case-control studies
Test Summary accuracy (95% CI) No. of participants (studies) Dementia prevalence Implications, quality and comments
AD-8
cut-off score 1
Sensitivity: 0.90 (0.81 to 0.96)
Specificity: 0.68 (0.62 to 0.74)
n = 324
(1 study)
n = 73
(60%)
The majority of studies used the
informant cut-of f score of 2 to def ine
AD-8 test posit ivity
As the cut-of f score is raised, there is
an increase in specif icity. Sensit ivity
is sim ilar at a cut-of f score of 2 or
3, but falls as the cut-of f score to
def ine test posit ivity rises
False posit ives (individuals wrongly
ident if ied as having possible demen-
t ia and referred for further invest iga-
t ions) and false negat ives (individu-
als with dementia who are not iden-
t if ied and not referred for specialist
assessment and management) can
both be associated with harms. If
used as a screening test (i.e. an ini-
t ial assessment, which will be fol-
lowed by further test ing) then a pat-
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tern of higher sensit ivity may be
preferable
The dementia prevalence within the
included studies was highly varied
(12% to 90%) and may ref lect that
for each cut-of f score, data were in-
cluded f rom all sett ings in which the
AD-8 has been used. These analyses
need to be interpreted with caut ion
as the propert ies of the test may vary
by sett ing and the desired balance
of sensit ivity and specif icity will vary
by purpose of test ing
AD-8 cut-off score 2 Sensitivity: 0.92
(0.86 to 0.96)
Specificity: 0.64
(0.39 to 0.82)
+LR: 2.53
(1.38 to 4.64)
- ve LR: 0.12
(0.07 to 0.21)
n = 3659
(7 studies)
n = 1016 (28%
range:
12% to 90%)
AD-8 cut-off score 3 Sensitivity: 0.91
(0.80 to 0.96)
Specificity: 0.76
(0.57 to 0.89)
+LR: 3.86
(2.03 to 7.34)
- ve LR: 0.12
(0.06 to 0.24)
n = 1060
(5 studies)
n = 396
(37%
range:
14% to 90%)
AD-8 cut-off score 7 Sensitivity: 0.83
(0.69 to 0.92)
Specificity: 0.90
(0.73 to 0.98)
n = 77
(1 study)
n = 47 (61%)
95%CI: 95% conf idence interval
+LR: posit ive likelihood rat io
-LR: negat ive likelihood rat io
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What is the accuracy of the AD-8 test for detection of dementia in different settings and using different languages of administration?
Population Adults whose informant completed an AD-8 quest ionnaire, with no restrict ions on the case mix of recruited part icipants
Setting Primary care, community and secondary care
Index test AD-8 informant-based quest ionnaire using a cut-of f score of 2 to def ine posit ivity
Reference standard Clinical diagnosis of dementia made using any recognised classif icat ion system
Studies We included cross-sect ional but not case-control studies
Comparative analyses
Test No. of participants (studies) Dementia prevalence Findings Implications
Community versus primary care
versus secondary care setting
Total n = 4045 (9)
n = 2937 (4) Community
n= 309 (1) Primary care
n = 716 (4) Secondary care
Total n = 1107 (27%)
Community n = 601 (20%)
Primary n = 44 (14%)
Secondary care n = 462 (65%)
Using a cut-of f score of 2, the AD-
8 has a higher relat ive sensit ivity
(1.11, 95%CI 1.02 to 1.21) in sec-
ondary care compared to commu-
nity care sett ings
Using a cut-of f score of 2, the AD-
8 has a lower relat ive specif icity
(0.51, 95%CI 0.23 to 1.09) in sec-
ondary care compared to commu-
nity care sett ings
Only one study used the AD-8 in
primary care sett ings; data were
at a cut-of f score of 3
Two studies used AD-8 in com-
munity and two studies used AD-
8 in secondary care sett ings, with
a cut-of f score of 3. The numbers
were insuf f icient to allow formal
quant itat ive synthesis
Dementia prevalence in sec-
ondary care is more than double
that seen in the community
The AD-8 has a higher sensit iv-
ity, but poorer specif icity, in sec-
ondary care sett ings
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English language Total: n = 1040 (5) English lan-
guage
Total n = 535 (51%) The test accuracy of English lan-
guage administrat ion of the AD-
8, at a cut-of f score of 2, has a
higher sensit ivity and lower speci-
f icity than summary est imates for
all studies at a cut-of f score of 2.
Est imates for specif icity were im-
precise due to the small number
of studies included
Sensit ivity: 0.95 (95% CI 0.87 to
0.98)
Specif icity: 0.59 (95% CI 0.21 to
0.89)
+LR: 2.30 (95%CI 0.87 to 6.07)
-LR: 0.08 (95% CI 0.03 to 0.22)
We were unable to assess English
language at a cut-of f score of 3
due to lack of available data at
this cut-of f score
We were unable to assess the non-
English-language group due to
the small numbers report ing lan-
guage of administrat ion clearly
There is a need to improve clarity
of report ing around language of
test administrat ion to evaluate di-
agnost ic accuracy of non-English-
language versions of the AD-8
95%CI: 95% conf idence interval
+LR: posit ive likelihood rat io
-LR: negat ive likelihood rat io
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D I S C U S S I O N
Summary of main results
This review summarises the test accuracy of the AD-8 for demen-
tia, across the range of settings in which it may be applied. Quan-
titative synthesis from seven of the identified studies suggests a
summary sensitivity of 0.92 and specificity of 0.64 when an AD-
8 cut-off score of two is used for the diagnosis of dementia. These
results are international and include a population of 3659 partici-
pants. Using an AD-8 cut-off score of three to diagnose dementia
achieves a similar sensitivity of 0.91, and higher specificity of 0.76,
based on data from five studies and 1060 participants. There was
significant clinical and methodological heterogeneity between the
included studies, regarding their study populations, and dementia
prevalence (which varied from 12% to 90%).
We found the usual pattern of compromise between sensitivity and
specificity at extremes of scoring (for example, an AD-8 score of
one versus an AD-8 score of seven). At the thresholds commonly
used in practice - cut-off scores of two or three - differences were
less obvious. Our summary estimates of test properties at these
scores have relatively large confidence intervals, particularly for
specificity; this reflects the heterogeneity in the included studies.
We can conclude that at usual threshold scores, the AD-8 favours
sensitivity over specificity. A cut-off of two was used most com-
monly, which is consistent with the original development of the
tool (Galvin 2005).
The setting of test administration affected the test accuracy es-
timates produced. Using a cut-off score of two, the AD-8 has
a higher relative sensitivity (1.11), but lower relative specificity
(0.51) in secondary care compared to community care settings.
This suggests use of the AD-8 in secondary care will produce more
false positive results in those referred for specialist assessment, but
fewer false negatives than when used in community cohorts. Ar-
guably, in those referred for a specialist assessment and having al-
ready had some form of cognitive testing, specificity is important.
In this case, our data would suggest that the AD-8 is less suited
as a diagnostic aid in a secondary-care memory-clinic setting. The
data at a cut-off score of three could not be pooled due to the small
number of studies in each setting group; similarly, only one study
examined the AD-8 in primary care.
Removal of the study with a low average age (prespecified as less
than 65 years) resulted in similar estimates of sensitivity (0.91),
but improved specificity (0.73). The excluded study still had a
mean age of greater than 60 years.
One study included only adults diagnosed as having delirium at
the time of presentation (Jackson 2016). Delirium is more likely
to occur in adults with a diagnosis of dementia (Inouye 2014), so
we performed a sensitivity analysis removing this from the pooled
estimate at a cut-off score of three. Removing this study resulted in
lower sensitivity and higher specificity than the summary estimate.
Quantitative analysis comparing the accuracy of different refer-
ence standard classifications was not possible due to the range of
different approaches used.
Analysis comparing the accuracy of different language versions of
the AD-8 was limited due to the unclear description of the version
used in two studies, and the lack of data available at a cut-off
score of three. The summary test accuracy of the English-language
version was comparable with the overall pooled estimate.
Strengths and weaknesses of the review
Strengths and weaknesses of included studies
Quality assessment using the QUADAS-2 tool identified risks of
bias and applicability concerns across all the included studies; we
assessed no study as having low risk on all domains. Specific con-
cerns are discussed in Characteristics of included studies and are
graphically presented in Figure 2. These included the potential for
selection bias introduced by exclusion criteria around comorbidi-
ties or unclear exclusion of participants; and issues around the con-
duct of index tests and suitability of informants, based on length
of relationship, age, etc. There was a lack of data from primary
care settings and acute hospital inpatient settings, which may be
targets for opportunistic assessment using brief instruments.
Strengths and weaknesses of review process
This review has been conducted using a rigorous search strategy,
developed and managed by an experienced Information Specialist
in Cochrane. The search was determined using a structured ap-
proach. No restrictions were placed based on date or language, and
translation services were used where necessary to facilitate the eval-
uation and inclusion of non-English-language publications. Our
correspondence with study authors was successful; we obtained ad-
ditional data, clarification around aspects that were unclear in the
original publication, and additional papers evaluating the AD-8
(Acknowledgements). Quality assessment was informed by use of
dementia-specific QUADAS-2 anchoring statements, which were
developed for this suite of reviews by experts in the field (Davis
2013).
Our review question was focused on evaluating the diagnostic ac-
curacy of the AD-8 for dementia, thus we excluded data evalu-
ating the AD-8 for diagnosing mild cognitive impairment from
our quantitative analyses. We conducted prespecified sensitivity
analyses around setting, studies of low average age, disease-specific
populations, and language of administration.
Comparisons with previous research
The AD-8 is one of two informant-based questionnaires whose
test accuracy for dementia has been assessed by the Cochrane De-
mentia and Cognitive Improvement Group; the other is the In-
formant Questionnaire on Cognitive Decline in the Elderly (IQ-
CODE). The IQCODE was found to have a similar test accuracy
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to the AD-8 in community settings (sensitivity 0.80; specificity
0.84; 10 studies; 2644 individuals) (Quinn 2014). In secondary
care settings, data were further divided into those evaluating the
IQCODE in specialistmemory settings and non-specialist settings
(Harrison 2015). In keeping with the current review, the majority
of the data in the IQCODE review were from specialist settings
and test accuracy estimates showed a higher specificity but com-
parable sensitivity (sensitivity 0.90; specificity 0.54; six studies;
1352 individuals) to the overall secondary care estimate for the
AD-8. The relative lack of AD-8 data from primary care settings
is consistent with the review of the IQCODE in primary care,
which identified only one relevant study in this setting (Harrison
2014).
The AD-8 was designed to differentiate cognitively normal indi-
viduals from those with mild dementia as part of clinical assess-
ment in a primary care setting, derived using data from a lon-
gitudinal community cohort study (Galvin 2005). Prevalence of
dementia was recognised to affect the test accuracy of the AD-
8, even at its inception (Galvin 2005). In the original validation
study, the inclusion of 56 individuals with mild to severe dementia
raised prevalence from 38% to 53%, improved sensitivity to 0.85
from 0.74 without a change to specificity of 0.86 (Galvin 2005).
The pooled estimates reported in this review of all-cause/all-sever-
ity dementia have a higher sensitivity, but poorer specificity, than
described in the first AD-8 report.
During the production of this review, another author group pub-
lished a systematic review of AD-8 test accuracy (Chen 2018).
Although the inclusion and exclusion criteria were similar, the re-
view did not include some studies that we included in our review.
It is not clear if these titles were considered and then rejected,
or not considered. For using the AD-8 to differentiate dementia
from normal cognition, the summary test accuracy data presented
in the review by Chen and colleagues were similar to our results,
with high sensitivity (0.91, 95% CI 0.89 to 0.92) and lower speci-
ficity (0.78, 95% CI 0.76 to 0.80) (Chen 2018). No assessment
of internal or external validity was presented.
We excluded case-control designs, in common with the other re-
views in the suite, due to the potential to over-estimate test accu-
racy (Rutjes 2006; Kohn 2013). The case-control studies excluded
from this review have been analysed, and a summary sensitivity
of 0.88 and specificity of 0.76 was reported (Anwer 2017). The
effect of combining these studies with the studies included in our
review has not been evaluated, however meta-regression analysis
did not show evidence of a systematic difference in the accuracy
reported for the AD-8 between non-case-control and case-control
designs (Anwer 2017).
Applicability of findings to the review question
This review focused on collating all available cross-sectional data
on the diagnostic accuracy of the AD-8 to identify dementia. Our
search strategy was robust and we believe we have evaluated all the
evidence relevant to this question. Summary estimates of AD-8 test
accuracy are provided where sufficient appropriate data allowed,
and findings are reported with consideration of study quality, risks
of bias and applicability associated with study conduct.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The AD-8 was developed as a tool to help inform the assessment
of an individual, rather than being a diagnostic test for dementia
in itself. The data from this review support the use of the AD-8
(informant cut-off score of two) as a tool to help identify those who
may benefit from further specialist assessment. The setting where
the test is administered affects the diagnostic accuracy, though we
could not evaluate estimates of performance in primary care using
the available data (albeit this may be the setting where the tool is
used most often).
Test accuracy is only one metric to consider when using a test
in clinical practice. For a test that is likely to be used predomi-
nantly in older adults, consideration must be given to feasibility,
acceptability and test burden (Lees 2017). The feasibility of using
the AD-8 in the range of settings reported cannot be fully deter-
mined from the included studies, as there was a lack of data on the
handling of indeterminate results or methods of assessing those
whose informant was not present. Lack of an available informant
was a common reason for exclusion, and one study excluded those
whose informant was considered ’unreliable’ due to age or per-
ceived knowledge of the individual (Larner 2015). As such, there
are insufficient data on the acceptability and feasibility of AD-8
use in practice to offer any useful comment on these properties.
In the context of a large and increasing variety of available cog-
nitive assessment tools (Harrison 2016), the important clinical
question is around which test to use for a particular patient. Our
review only goes some way to answering this question. We offer
data on a single test, rather than formal comparative analyses with
other tests. Techniques to allow comparisons across a network of
differing tests with a common reference standard are emerging and
may be a useful approach for future reviews (Owen 2018).
There is no ideal value for sensitivity or specificity in clinical prac-
tice. The optimal ’trade-off ’ between sensitivity and specificity will
depend on the purpose of testing and the implications of erro-
neous test results. With a pattern of high sensitivity and lower
specificity, the AD-8 is best suited for use as an initial screening or
triage tool, with a view to selecting those who need more detailed
assessment. In this scenario, the higher ’false positives’ will go on to
have additional testing and an incorrect label of dementia should
be avoided. This form of cognitive screening is the usual purpose
for which the AD-8 is employed in clinical practice and our review
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data would support this approach. It is interesting that the pattern
of high sensitivity and lower specificity seems more pronounced
when the AD-8 is used in a secondary care (specialist memory
service) setting. In this setting, where there is a high prevalence of
cognitive impairment and the population is likely to have already
had some form of cognitive assessment before referral, the utility
of a high-sensitivity screening tool is questionable.
Implications for research
In this review, we observed differences in test accuracy when the
AD-8 was used in different healthcare settings. It is therefore im-
portant that future studies stratify results by the setting of recruit-
ment, and that researchers are aware of the differences in dementia
prevalence which may affect test performance. We only identified
one study that was conducted in each of the primary care and acute
hospital settings. These settings may provide opportunities for the
use of brief cognitive tests such as the AD-8, and thus diagnostic
accuracy should be established.
This review considered only the use of the AD-8 as a single test in
isolation. In practice, it is likely that testing is done sequentially,
informed by results. This review is one in a series examining the
test accuracy of other dementia tests, including the Informant
Questionnaire on Cognitive Decline in the Elderly (Harrison
2015), andMontreal Cognitive Assessment (Davis 2015). Itwould
be helpful to consider the testing pathway and determine which
tests have greatest diagnostic utility at which stage. Tests may not
be used sequentially and informant assessments such as the AD-8
are often completed at the same time as direct-to-patient cognitive
tests. How these results should be combined to give the greatest
accuracy is a topic that requires further research.
In applying our assessments of internal and external validity, use
of the QUADAS-2 tool was complicated by poor reporting within
the included studies. Poor reporting is a recognised issue in test
accuracy studies (Davis 2013). Specific guidance for reporting test
accuracy with a dementia focus is available, and we would recom-
mend that future primary test accuracy research makes use of this
resource (Noel-Storr 2014).
The ultimate goal of interventions to improve rates of dementia
diagnosis is to enable individuals to access specialist services, re-
sources and support. Historical modelling suggested early diagno-
sis could improve the quality of life of those diagnosed, and reduce
the need for care-home admission (Banerjee 2009). Longitudinal
data from the UK identified evidence of increased rates of de-
mentia diagnosis and reductions in antipsychotic prescribing fol-
lowing introduction of theNational Dementia Strategy (Donegan
2017). A challenge is therefore for researchers to identify if those
identified as having possible dementia and referred for formal di-
agnosis derive benefit from the impact of this diagnosis through
the care and treatment they subsequently receive. Ultimately, the
design of studies looking at assessment tools such as the AD-8
may move away from the classical index test versus gold-standard
paradigm to a model that looks at test-treatment-outcome path-
ways (Takwoingi 2018).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chan 2016
Study characteristics
Patient sampling Patient-informant dyads were recruited in two phases.
Phase I (screening): “participants were recruited if they were aged 60 and above, had provided
informed consent, and had a suitable informant with frequent interactions for at least 10 hours.”
Phase II (validation): “participants were recruited if they had completed phase 1, provided informed
consent, and had no physical disabilities that affected their ability to perform the cognitive assess-
ments.” Participants underwent additional evaluations
Most exclusions were due to patient choice; no other exclusion criteria were specified
Patient characteristics and set-
ting
Patients at government-subsidised primary healthcare settings aged over 60 years
Index tests AD-8 Chinese and Malay translations
Target condition and reference
standard(s)
DSM-IV criteria and CDR global scores used to determine presence of dementia and severity
Flow and timing There probably is a gap between Phase I and Phase II, but the duration is not specified or explained
Comparative
Notes All patients whomade it to Phase II were included, but more than 90% of the patients found eligible
for Phase I were lost
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear Low
DOMAIN 2: Index Test All tests
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Chan 2016 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Unclear Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Unclear
Were all patients included in the
analysis?
No
High
Chio 2017
Study characteristics
Patient sampling Patients were recruited from two neurology outpatient clinics. Patients with subjective or objective
memory complaints were referred by physicians
Exclusions:
1. diagnosis of psychological disorder other than dementia;
2. inability to communicate verbally.
Participants who scored CDR of higher than 2 were excluded from further analysis
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Chio 2017 (Continued)
Patient characteristics and set-
ting
Patients recruited from neurology outpatient clinics
Physician referrals if they had subjective or objective memory complaints
Index tests AD-8. It is unclear whether the test was translated or conducted in English
Target condition and reference
standard(s)
CDR
Early cognitive impairment
Flow and timing The timing between questionnaire and data collection varies between participants and is not de-
scribed in detail
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Unclear
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Chio 2017 (Continued)
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
Unclear
Correia 2011
Study characteristics
Patient sampling “The elderly were identified and invited to participate in the survey”
Sample size was pre-calculated based on total population and dementia prevalence in that population
(aimed to recruit 111 participants which included a 10% surplus)
Study does not state how these specific participants were selected from a population of 18,904
elderly
However, dementia prevalence was found to be 13.8%, so not vastly over the stated dementia
prevalence of the whole target population (7.1%)
The only stated exclusion criterion is not having a relative who has known the individual for over
10 years; it is unclear if there were others
Patient characteristics and set-
ting
Community-dwelling elderly aged 65 years and over in a city in Brazil
Index tests AD-8, Portuguese translation
Target condition and reference
standard(s)
DSM-IV
Carried out independently and blinded to AD-8 results
Combination of patient and informant assessment
Flow and timing Clinical assessment and independent informant questionnaire performed on same day
Comparative
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Correia 2011 (Continued)
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Correia 2011 (Continued)
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Galvin 2006
Study characteristics
Patient sampling Consecutive sample of patients referred to memory clinic
Patient characteristics and set-
ting
Memory clinic referrals
Index tests AD-8
Target condition and reference
standard(s)
Clinical diagnosis made using various diagnostic criteria including DSM
Flow and timing Clinical assessment and informant assessment within one week of each other
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
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Galvin 2006 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Unclear Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
Unclear
Galvin 2007
Study characteristics
Patient sampling Consecutive patient-informant dyads enrolled in a longitudinal study
Patient characteristics and set-
ting
Community-dwelling volunteers
Index tests AD-8
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Galvin 2007 (Continued)
Target condition and reference
standard(s)
CDR used to determine presence or absence of dementia and to stage its severity. Authors classified
CDR 0.5 as mild dementia
Flow and timing Timing of clinical assessment and informant questionnaire not clear
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
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Galvin 2007 (Continued)
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
Unclear
Jackson 2016
Study characteristics
Patient sampling Consecutive, consenting older adult admissions to a UK hospital with delirium
Patient characteristics and set-
ting
All patients had delirium at time of recruitment, so results may not be applicable to an unselected
cohort
Index tests AD-8
Target condition and reference
standard(s)
Diagnostic interview based on DSM-IV performed at three months post-delirium, to assess pre-
delirium dementia
Flow and timing Of 228 with delirium, only 125 contributed data. Diagnostic interview was performed at least three
months following questionnaire administration, in context of acute illness there may have been
important cognitive change in this time
Comparative
Notes Main reason for non-contribution data was lack of an informant
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
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Jackson 2016 (Continued)
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low High
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
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Larner 2015
Study characteristics
Patient sampling Consecutive patient-informant dyads recruited prospectively
Exclusions: (1) patients without an informant; (2) patients with an unreliable informant, which
consisted of informants with insufficient knowledge, dementia already diagnosed, language barriers
and very young informant
Patient characteristics and set-
ting
Referrals to the Cognitive Function Clinic at a regional neuroscience centre
Index tests AD-8
Target condition and reference
standard(s)
Cognitive impairment
DSM IV was used, as well as looking at patient history for cognitive symptoms and functional
performance, neuroradiological examination, neuropsychological assessment
Diagnosis was performed at the discretion of an experienced clinician
Flow and timing Clinical and informant assessment performed on the same day. Large numbers attended alone (i.e.
no informant) and so were not included in analysis
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Low Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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Larner 2015 (Continued)
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
Unclear
Meguro 2015
Study characteristics
Patient sampling Community residents volunteered
Patient characteristics and set-
ting
Community residents aged 75 years and older in Northern Japan
Index tests AD-8 (Japanese translation)
Target condition and reference
standard(s)
CDR
Flow and timing Insufficient information to draw a flow chart
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Meguro 2015 (Continued)
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
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Meguro 2015 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Unclear
Were all patients included in the
analysis?
Unclear
Unclear
Razavi 2014
Study characteristics
Patient sampling Consecutive sample frommemory clinic plus patients from a neurology clinic. Sample was ’enriched’
with cognitively normal control patients
33 patients with comorbid medical conditions that could potentially affect cognition but were not
dementias were excluded
Patient characteristics and set-
ting
Mixed population from various referral pathways
Index tests AD-8
Target condition and reference
standard(s)
The study states that it uses “published criteria” but does not further operationalise
Flow and timing 33 patients with comorbid medical conditions that could potentially affect cognition but were not
dementias were excluded. The timing of clinical and informant assessment is not clear
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Unclear
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Razavi 2014 (Continued)
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
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Yang 2016
Study characteristics
Patient sampling A cross-sectional survey was administered in 4 communities across 12 counties in the Zhejiang
province using multi-stage stratified random cluster sampling
12 administrative districts were divided into 4 type districts, based on economic levels. One district
was systematically chosen from each of the 4 district types
Inclusion criteria: (1) subjects aged 65 years or older; (2) subjects could complete CDT; (3) subjects/
informants could sign consent
Exclusion criteria: subjects who had any of the following conditions: (1) acute severe disease such
as acute myocardial infarction, acute cerebral infarction and other severe heart, brain, kidney and
liver disease; (2) severe deafness or aphasia or subjects who did not consent
Patient characteristics and set-
ting
Patients were aged 65 years and older living at home or in an institution in the Zhejiang province
Index tests AD-8, unclear which language used
Target condition and reference
standard(s)
Dementia
NIA-AA criteria
Flow and timing Timing of assessments is not described.
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Unclear
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
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Yang 2016 (Continued)
If a threshold was used, was it
pre-specified?
Yes
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
CDR: Clinical Dementia Rating scale
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
NIA-AA: National Institute on Aging and Alzheimer’s Association
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Basalo 2017 Inappropriate index test
Blanco 2016 Case-control study
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(Continued)
Carnero 2013 Case-control study
Carpenter 2011 No dementia diagnosis reference standard
Carpenter 2011ii No dementia diagnosis reference standard
Chen 2017 AD-8 completed by patients
Chen 2018 No original data
Chin 2013 AD-8 completed by patients
Dong 2013 Case-control study
Dong 2014 No dementia diagnosis reference standard
Dyer 2017 No dementia diagnosis reference standard
Galvin 2005 Scale development paper, data incorporated in larger dataset included in analysis
Galvin 2007ii Same dataset as included paper
Galvin 2010 No dementia diagnosis reference standard
Gottesman 2018 No dementia diagnosis reference standard
Hsieh 2015 Case report
Li 2012 Case-control study
Malmstrom 2009 The study subgroup which could have been eligible did not include any participants with a cognitive diagnosis
compatible with our prespecified criteria for dementia
Munoz 2010 Case-control study
Overton 2013 Case-control study
Pardo 2013 Case-control study (also no useable DTA data)
Ryu 2009 Case-control study
Tew 2015 Case-control study
Wojtowicz 2017 Same dataset as included paper
Xie 2014 No dementia diagnosis reference standard (also AD-8 completed by patients)
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(Continued)
Yang 2011 Case-control study
DTA: diagnostic test accuracy
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D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 AD-8 informant cutpoint 1 1 324
2 AD-8 informant cutpoint 2 7 3659
3 AD-8 informant cutpoint 3 5 1060
4 AD-8 informant cutpoint 7 1 77
5 Sensitivity analysis removing low
average age
6 3447
6 Sensitivity analysis removing
disease-specific study
4 983
7 English language studies -
cutpoint 2
4 963
8 English language studies -
cutpoint 3
3 642
9 Sensitivity analysis removing
CDR 0.5 - cutpoint 2
6 3335
10 Sensitivity analysis removing
CDR 0.5 - cutpoint 3
4 736
Test 1. AD-8 informant cutpoint 1.
Review: AD-8 for detection of dementia across a variety of healthcare settings
Test: 1 AD-8 informant cutpoint 1
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Galvin 2007 66 80 7 171 0.90 [ 0.81, 0.96 ] 0.68 [ 0.62, 0.74 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 2. AD-8 informant cutpoint 2.
Review: AD-8 for detection of dementia across a variety of healthcare settings
Test: 2 AD-8 informant cutpoint 2
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Correia 2011 11 37 4 57 0.73 [ 0.45, 0.92 ] 0.61 [ 0.50, 0.71 ]
Galvin 2006 200 13 17 11 0.92 [ 0.88, 0.95 ] 0.46 [ 0.26, 0.67 ]
Galvin 2007 61 18 12 233 0.84 [ 0.73, 0.91 ] 0.93 [ 0.89, 0.96 ]
Larner 2015 67 127 2 16 0.97 [ 0.90, 1.00 ] 0.11 [ 0.07, 0.18 ]
Meguro 2015 61 161 8 342 0.88 [ 0.78, 0.95 ] 0.68 [ 0.64, 0.72 ]
Razavi 2014 128 15 1 42 0.99 [ 0.96, 1.00 ] 0.74 [ 0.60, 0.84 ]
Yang 2016 398 339 46 1232 0.90 [ 0.86, 0.92 ] 0.78 [ 0.76, 0.80 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 3. AD-8 informant cutpoint 3.
Review: AD-8 for detection of dementia across a variety of healthcare settings
Test: 3 AD-8 informant cutpoint 3
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Chan 2016 40 24 4 241 0.91 [ 0.78, 0.97 ] 0.91 [ 0.87, 0.94 ]
Correia 2011 15 31 0 63 1.00 [ 0.78, 1.00 ] 0.67 [ 0.57, 0.76 ]
Galvin 2006 195 8 22 16 0.90 [ 0.85, 0.94 ] 0.67 [ 0.45, 0.84 ]
Galvin 2007 55 25 18 226 0.75 [ 0.64, 0.85 ] 0.90 [ 0.86, 0.93 ]
Jackson 2016 46 18 1 12 0.98 [ 0.89, 1.00 ] 0.40 [ 0.23, 0.59 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 4. AD-8 informant cutpoint 7.
Review: AD-8 for detection of dementia across a variety of healthcare settings
Test: 4 AD-8 informant cutpoint 7
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jackson 2016 39 3 8 27 0.83 [ 0.69, 0.92 ] 0.90 [ 0.73, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 5. Sensitivity analysis removing low average age.
Review: AD-8 for detection of dementia across a variety of healthcare settings
Test: 5 Sensitivity analysis removing low average age
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Correia 2011 11 37 4 57 0.73 [ 0.45, 0.92 ] 0.61 [ 0.50, 0.71 ]
Galvin 2006 200 13 17 11 0.92 [ 0.88, 0.95 ] 0.46 [ 0.26, 0.67 ]
Galvin 2007 61 18 12 233 0.84 [ 0.73, 0.91 ] 0.93 [ 0.89, 0.96 ]
Meguro 2015 61 161 8 342 0.88 [ 0.78, 0.95 ] 0.68 [ 0.64, 0.72 ]
Razavi 2014 128 15 1 42 0.99 [ 0.96, 1.00 ] 0.74 [ 0.60, 0.84 ]
Yang 2016 398 339 46 1232 0.90 [ 0.86, 0.92 ] 0.78 [ 0.76, 0.80 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 6. Sensitivity analysis removing disease-specific study.
Review: AD-8 for detection of dementia across a variety of healthcare settings
Test: 6 Sensitivity analysis removing disease-specific study
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Chan 2016 40 24 4 241 0.91 [ 0.78, 0.97 ] 0.91 [ 0.87, 0.94 ]
Correia 2011 15 31 0 63 1.00 [ 0.78, 1.00 ] 0.67 [ 0.57, 0.76 ]
Galvin 2006 195 8 22 16 0.90 [ 0.85, 0.94 ] 0.67 [ 0.45, 0.84 ]
Galvin 2007 55 25 18 226 0.75 [ 0.64, 0.85 ] 0.90 [ 0.86, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 7. English language studies - cutpoint 2.
Review: AD-8 for detection of dementia across a variety of healthcare settings
Test: 7 English language studies - cutpoint 2
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Galvin 2006 200 13 17 11 0.92 [ 0.88, 0.95 ] 0.46 [ 0.26, 0.67 ]
Galvin 2007 61 18 12 233 0.84 [ 0.73, 0.91 ] 0.93 [ 0.89, 0.96 ]
Larner 2015 67 127 2 16 0.97 [ 0.90, 1.00 ] 0.11 [ 0.07, 0.18 ]
Razavi 2014 128 15 1 42 0.99 [ 0.96, 1.00 ] 0.74 [ 0.60, 0.84 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 8. English language studies - cutpoint 3.
Review: AD-8 for detection of dementia across a variety of healthcare settings
Test: 8 English language studies - cutpoint 3
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Galvin 2006 195 8 22 16 0.90 [ 0.85, 0.94 ] 0.67 [ 0.45, 0.84 ]
Galvin 2007 55 25 18 226 0.75 [ 0.64, 0.85 ] 0.90 [ 0.86, 0.93 ]
Jackson 2016 46 18 1 12 0.98 [ 0.89, 1.00 ] 0.40 [ 0.23, 0.59 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 9. Sensitivity analysis removing CDR 0.5 - cutpoint 2.
Review: AD-8 for detection of dementia across a variety of healthcare settings
Test: 9 Sensitivity analysis removing CDR 0.5 - cutpoint 2
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Correia 2011 11 37 4 57 0.73 [ 0.45, 0.92 ] 0.61 [ 0.50, 0.71 ]
Galvin 2006 200 13 17 11 0.92 [ 0.88, 0.95 ] 0.46 [ 0.26, 0.67 ]
Larner 2015 67 127 2 16 0.97 [ 0.90, 1.00 ] 0.11 [ 0.07, 0.18 ]
Meguro 2015 61 161 8 342 0.88 [ 0.78, 0.95 ] 0.68 [ 0.64, 0.72 ]
Razavi 2014 128 15 1 42 0.99 [ 0.96, 1.00 ] 0.74 [ 0.60, 0.84 ]
Yang 2016 398 339 46 1232 0.90 [ 0.86, 0.92 ] 0.78 [ 0.76, 0.80 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 10. Sensitivity analysis removing CDR 0.5 - cutpoint 3.
Review: AD-8 for detection of dementia across a variety of healthcare settings
Test: 10 Sensitivity analysis removing CDR 0.5 - cutpoint 3
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Chan 2016 40 24 4 241 0.91 [ 0.78, 0.97 ] 0.91 [ 0.87, 0.94 ]
Correia 2011 15 31 0 63 1.00 [ 0.78, 1.00 ] 0.67 [ 0.57, 0.76 ]
Galvin 2006 195 8 22 16 0.90 [ 0.85, 0.94 ] 0.67 [ 0.45, 0.84 ]
Jackson 2016 46 18 1 12 0.98 [ 0.89, 1.00 ] 0.40 [ 0.23, 0.59 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. Summary of test accuracy at study level by dementia prevalence
Study Included participants
(n)
Dementia
n (%)
AD-8 Threshold Sensitivity
(%)
Specificity
(%)
Galvin 2006 241 217 (90) 2 92 46
Galvin 2006 241 217 (90) 3 89 67
Razavi 2014 186 129 (69) 2 99 74
Jackson 2016 77 47 (61) 3 98 40
Larner 2015 212 69 (33) 2 97 11
Galvin 2007 324 73 (23) 2 84 93
Galvin 2007 324 73 (23) 3 75 90
Yang 2016 2015 444 (22) 2 90 78
Correia 2011 109 15 (14) 2 73 61
Correia 2011 109 15 (14) 3 100 67
Chan 2016 309 44 (14) 3 91 91
Meguro 2015 572 69 (12) 2 88 68
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Table 1. Summary of test accuracy at study level by dementia prevalence (Continued)
Where multiple thresholds were reported in the primary paper, we present the data for both a cut-off score of 2 and 3
The total number of participants is adjusted to reflect the data used in quantitative synthesis
A P P E N D I C E S
Appendix 1. WHO International Classification of Disease - Dementia
F00 - F09 ORGANIC, INCLUDING SYMPTOMATIC, MENTAL DISORDERS
DEMENTIA
G1. Evidence of each of the following.
(1) A decline in memory, which is most evident in the learning of new information, although in more severe cases, the recall of
previously learned information may be also affected. The impairment applies to both verbal and non-verbal material. The decline
should be objectively verified by obtaining a reliable history from an informant, supplemented, if possible, by neuropsychological tests
or quantified cognitive assessments. The severity of the decline, with mild impairment as the threshold for diagnosis, should be assessed
as follows.
Mild: a degree ofmemory loss sufficient to interfere with everyday activities, though not so severe as to be incompatible with independent
living. The main function affected is the learning of new material. For example, the individual has difficulty in registering, storing and
recalling elements in daily living, such as where belongings have been put, social arrangements, or information recently imparted by
family members.
Moderate: a degree of memory loss which represents a serious handicap to independent living. Only highly learned or very familiar
material is retained. New information is retained only occasionally and very briefly. The individual is unable to recall basic information
about where he lives, what he has recently been doing, or the names of familiar persons.
Severe: a degree of memory loss characterized by the complete inability to retain new information. Only fragments of previously learned
information remain. The subject fails to recognise even close relatives.
(2) A decline in other cognitive abilities characterized by deterioration in judgement and thinking, such as planning and organizing,
and in the general processing of information. Evidence for this should be obtained when possible from interviewing an informant,
supplemented, if possible, by neuropsychological tests or quantified objective assessments. Deterioration from a previously higher level
of performance should be established. The severity of the decline, with mild impairment as the threshold for diagnosis, should be
assessed as follows.
Mild: the decline in cognitive abilities causes impaired performance in daily living, but not to a degree making the individual dependent
on others. More complicated daily tasks or recreational activities cannot be undertaken.
Moderate: the decline in cognitive abilities makes the individual unable to function without the assistance of another in daily living,
including shopping and handling money. Within the home, only simple chores are preserved. Activities are increasingly restricted and
poorly sustained.
Severe: the decline is characterised by an absence, or virtual absence, of intelligible ideation. The overall severity of the dementia is best
expressed as the level of decline in memory or other cognitive abilities, whichever is the more severe (e.g. mild decline in memory and
moderate decline in cognitive abilities indicate a dementia of moderate severity).
G2. Preserved awareness of the environment during a period of time long enough to enable the unequivocal demonstration of G1.
When there are superimposed episodes of delirium the diagnosis of dementia should be deferred.
G3. A decline in emotional control or motivation, or a change in social behaviour, manifest as at least one of the following:
1. emotional lability;
2. irritability;
3. apathy;
4. coarsening of social behaviour.
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G4. For a confident clinical diagnosis, G1 should have been present for at least six months; if the period since the manifest onset is
shorter, the diagnosis can only be tentative.
Comments: the diagnosis is further supported by evidence of damage to other higher cortical functions, such as aphasia, agnosia,
apraxia.
Judgement about independent living or the development of dependence (upon others) need to take account of the cultural expectation
and context.
Dementia is specified here as having a minimum duration of six months to avoid confusion with reversible states with identical
behavioural syndromes, such as traumatic subdural haemorrhage (S06.5), normal pressure hydrocephalus (G91.2) and diffuse or focal
brain injury (S06.2 and S06.3).
A fifth character may be used to indicate the presence of additional symptoms, in the categories F00-F03 (F00 Dementia in Alzheimer’s
disease; F01 Vascular dementia; F02 Dementia in diseases classified elsewhere; and F03 Unspecified dementia), as follows:
.x0 without additional symptoms
.x1 with other symptoms, predominantly delusional
.x2 with other symptoms, predominantly hallucinatory
.x3 with other symptoms, predominantly depressive
.x4 with other mixed symptoms
A sixth character may be used to indicate the severity of the dementia:
.xx0 mild
.xx1 moderate
.xx2 severe
As mentioned above the overall severity of the dementia depends on the level of memory or intellectual impairment, whichever is the
more severe.
F00 DEMENTIA IN ALZHEIMER’S DISEASE
A. The general criteria for dementia (G1 to G4) must be met.
B. There is no evidence from the history, physical examination or special investigations for any other possible cause of dementia (e.g.
cerebrovascular disease, Parkinson’s disease, Huntington’s disease, normal pressure hydrocephalus), a systemic disorder (e.g. hypothy-
roidism, vit. B12 or folic acid deficiency, hypercalcaemia), or alcohol- or drug-abuse.
Comments: The diagnosis is confirmed by post mortem evidence of neurofibrillary tangles and neuritic plaques in excess of those found
in normal ageing of the brain.
The following features support the diagnosis, but are not necessary elements: Involvement of cortical functions as evidenced by aphasia,
agnosia or apraxia; decrease of motivation and drive, leading to apathy and lack of spontaneity; irritability and disinhibition of social
behaviour; evidence from special investigations that there is cerebral atrophy, particularly if this can be shown to be increasing over
time. In severe cases there may be Parkinson-like extrapyramidal changes, logoclonia, and epileptic fits.
Specification of features for possible subtypes. Because of the possibility that subtypes exist, it is recommended that the following
characteristics be ascertained as a basis for a further classification: age at onset; rate of progression; the configuration of the clinical
features, particularly the relative prominence (or lack) of temporal, parietal or frontal lobe signs; any neuropathological or neurochemical
abnormalities, and their pattern.
The division of AD into subtypes can at present be accomplished in two ways: first by taking only the age of onset and labelling AD as
either early or late, with an approximate cut-off point at 65 years; or secondly, by assessing how well the individual conforms to one of
the two putative syndromes, early or late onset type. It should be noted that it is unlikely that a sharp distinction exists between early
and late onset type. Early onset type may occur in late life, just as late onset type may occasionally have an onset under the age of 65.
The following criteria may be used to differentiate F00.0 from F00.1, but it should be remembered that the status of this subdivision
is still controversial.
F00.0 Dementia in Alzheimer’s disease with early onset
1. The criteria for dementia in Alzheimer’s disease (F00) must be met, and the age at onset being under 65 years.
2. In addition, at least one of the following requirements must be met:
(a) evidence of a relatively rapid onset and progression;
(b) in addition to memory impairment, there is aphasia (amnesic or sensory), agraphia, alexia, acalculia, or apraxia (indicating the
presence of temporal, parietal and/or frontal lobe involvement).
F00.1 Dementia in Alzheimer’s disease with late onset
1. The criteria for dementia in Alzheimer’s disease (F00) must be met and the age at onset must be 65 or more.
2. In addition, at least one of the following requirements must be met:
61AD-8 for detection of dementia across a variety of healthcare settings (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(a) evidence of a very slow, gradual onset and progression (the rate of the latter may be known only retrospectively after a course of 3
years or more);
(b) predominance of memory impairment G1.1, over intellectual impairment G1.2 (see general criteria for dementia).
F00.2 Dementia in Alzheimer’s disease, atypical or mixed type
Use this term and code for dementias that have important atypical features or that fulfil criteria for both early and late onset type of
Alzheimer’s disease. Mixed Alzheimer’s and vascular dementia is also included here.
F00.9 Dementia in Alzheimer’s disease, unspecified
F01 VASCULAR DEMENTIA
G1. The general criteria for dementia (G1 to G4) must be met.
G2. Unequal distribution of deficits in higher cognitive functions, with some affected and others relatively spared. Thus memory may
be quite markedly affected while thinking, reasoning and information processing may show only mild decline.
G3. There is clinical evidence of focal brain damage, manifest as at least one of the following:
(1) unilateral spastic weakness of the limbs;
(2) unilaterally increased tendon reflexes;
(3) an extensor plantar response;
(4) pseudobulbar palsy.
G4. There is evidence from the history, examination, or tests, of a significant cerebrovascular disease, which may reasonably be judged
to be etiologically related to the dementia (e.g. a history of stroke; evidence of cerebral infarction).
The following criteria may be used to differentiate subtypes of vascular dementia, but it should be remembered that the usefulness of
this subdivision may not be generally accepted.
F01.0 Vascular dementia of acute onset
A. The general criteria for vascular dementia (F01) must be met.
B. The dementia develops rapidly (i.e. usually within one month, but within no longer than three months) after a succession of strokes,
or (rarely) after a single large infarction.
F01.1 Multi-infarct dementia
A. The general criteria for vascular dementia (F01) must be met.
B. The onset of the dementia is gradual (i.e. within three to six months), following a number of minor ischaemic episodes.
Comments: It is presumed that there is an accumulation of infarcts in the cerebral parenchyma. Between the ischaemic episodes there
may be periods of actual clinical improvement.
F01.2 Subcortical vascular dementia
A. The general criteria for vascular dementia (F01) must be met.
B. A history of hypertension.
C. Evidence from clinical examination and special investigations of vascular disease located in the deep white matter of the cerebral
hemispheres, with preservation of the cerebral cortex.
F01.3 Mixed cortical and subcortical vascular dementia
Mixed cortical and subcortical components of the vascular dementia may be suspected from the clinical features, the results of
investigations (including autopsy), or both.
F01.8 Other vascular dementia
F01.9 Vascular dementia, unspecified
F02 DEMENTIA IN OTHER DISEASES CLASSIFIED ELSEWHERE
F02.0 Dementia in Pick’s disease
A. The general criteria for dementia (G1 to G4) must be met.
B. Slow onset with steady deterioration.
C. Predominance of frontal lobe involvement evidenced by two or more of the following:
(1) emotional blunting;
(2) coarsening of social behaviour;
(3) disinhibition;
(4) apathy or restlessness;
(5) aphasia.
D. Relative preservation, in the early stages, of memory and parietal lobe functions.
F02.1 Dementia in Creutzfeldt-Jakob disease
A. The general criteria for dementia (G1 to G4) must be met.
B. Very rapid progression of the dementia, with disintegration of virtually all higher cerebral functions.
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C. The emergence, usually after or simultaneously with the dementia, of one or more of the following types of neurological symptoms
and signs:
(1) pyramidal symptoms;
(2) extrapyramidal symptoms;
(3) cerebellar symptoms;
(4) aphasia;
(5) visual impairment.
Comments: An akinetic and mute state is the typical terminal stage. An amyotrophic variant may be seen, where the neurological signs
precede the onset of the dementia. A characteristic electroencephalogram (periodic spikes against a slow and low voltage background),
if present in association with the above clinical signs, will increase the probability of the diagnosis. However, the diagnosis can be
confirmed only by neuropathological examination (neuronal loss, astrocytosis, and spongiform changes). Because of the risk of infection,
this should be carried out only under special protective conditions.
F02.2 Dementia in Huntington’s disease
A. The general criteria for dementia (G1 to G4) must be met.
B. Subcortical functions are affected first and dominate the picture of dementia throughout; manifest as slowness of thinking or
movement and personality alteration with apathy or depression.
C. Presence of involuntary choreiform movements, typically of the face, hands or shoulders, or in the gait. The patient may attempt to
conceal them by converting them into a voluntary action.
D. A history of Huntington’s disease in one parent or a sibling; or a family history which suggests the disorder.
E. The absence of clinical features otherwise accounting for the abnormal movements.
Comments: In addition to involuntary choreiform movements there may be development of extrapyramidal rigidity or spasticity with
pyramidal signs.
F02.3 Dementia in Parkinson’s disease
A. The general criteria for dementia (G1 to G4) must be met.
B. Diagnosis of Parkinson’s disease.
C. Absence of cognitive impairment attributable to anti-parkinsonian medication.
D. There is no evidence from the history, physical examination or special investigations for any other possible cause of dementia,
including other forms of brain disease, damage or dysfunction (e.g. cerebrovascular disease, HIV disease, Huntington’s disease, normal
pressure hydrocephalus), a systemic disorder (e.g. hypothyroidism, vit. B12 or folic acid deficiency, hypercalcaemia), or alcohol or drug
abuse.
If criteria are also fulfilled for dementia in Alzheimer’s disease with late onset (F00.1), this category F00.1 should be used in combination
with Parkinson’s disease G20.
F02.4 Dementia in human immunodeficiency (HIV) disease
A. The general criteria for dementia (G1 to G4) must be met.
B. Diagnosis of HIV infection.
C. There is no evidence from the history, physical examination or special investigations for any other possible cause of dementia,
including other forms of brain disease, damage or dysfunction (e.g. Alzheimer’s disease, cerebrovascular disease, Parkinson’s disease,
Huntington’s disease, normal pressure hydrocephalus), a systemic disorder (e.g. hypothyroidism, vit. B12 or folic acid deficiency,
hypercalcaemia), or alcohol or drug abuse.
F02.8 Dementia in other specified diseases classified elsewhere
Dementia can occur as a manifestation or consequence of a variety of cerebral and somatic conditions. To specify the etiology, the ICD-
10 code for the underlying condition should be added.
F03 UNSPECIFIED DEMENTIA
This category should be used when the general criteria for dementia are met, but when it is not possible to identify one of the specific
types (F00.0-F02.9).
Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision
Dementia Codes
Dementia of the Alzheimer’s Type, with early onset
294.10 Without behavioural disturbance
294.11 With behavioural disturbance
Dementia of the Alzheimer’s Type, with late onset
294.10 Without behavioural disturbance
294.11 With behavioural disturbance
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Vascular dementia
290.40 Uncomplicated
290.41 With delirium
290.42 With delusions
290.43 With depressed mood
Dementia due to HIV disease
294.10 Without behavioural disturbance
294.11 With behavioural disturbance
Dementia due to head trauma
294.10 Without behavioural disturbance
294.11 With behavioural disturbance
Dementia due to Parkinson’s disease
294.10 Without behavioural disturbance
294.11 With behavioural disturbance
Dementia due to Huntington’s disease
294.10 Without behavioural disturbance
294.11 With behavioural disturbance
Dementia due to Pick’s disease
294.10 Without behavioural disturbance
294.11 With behavioural disturbance
Dementia due to Creutzfeldt-Jakob Disease
294.10 Without behavioural disturbance
294.11 With behavioural disturbance
Dementia due to... [indicate other general medical condition]
294.10 Without behavioural disturbance
294.11 With behavioural disturbance
294.8 Dementia NOS
Appendix 2. AD8 Informant Questionnaire
Remember, “Yes, a change” in-
dicates that there has been a
change in the last several years
caused by cognitive (thinking
and memory) problems
YES
A change
NO
No change
N/A
Don’t know
1. Problems with judgment (e.
g., problems making decisions,
bad financial decisions, prob-
lems with thinking)
2. Less interest in hobbies/ac-
tivities
3. Repeats the same things over
and over (questions, stories, or
statements)
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(Continued)
4. Trouble learning how to use
a tool, appliance, or gadget (e.
g., VCR, computer, microwave,
remote control)
5.Forgets correctmonth or year
6. Trouble handling compli-
cated financial affairs (e.g.
balancing checkbook, income
taxes, paying bills)
7. Trouble remembering ap-
pointments
8. Daily problems with think-
ing and/or memory
TOTAL AD-8 SCORE
Appendix 3. AD-8 administration and scoring guidelines
A spontaneous self-correction is allowed for all responses without counting as an error.
The questions are given to the respondent on a clipboard for self-administration or can be read aloud to the respondent either in person
or over the phone. It is preferable to administer the AD-8 to an informant, if available. If an informant is not available, the AD-8 may
be administered to the patient.
When administered to an informant, specifically ask the respondent to rate change in the patient.
When administered to the patient, specifically ask the patient to rate changes in his/her ability for each of the items,without attributing
causality.
If read aloud to the respondent, it is important for the clinician to carefully read the phrase as worded and give emphasis to note changes
due to cognitive problems (not physical problems).
There should be a one second delay between individual items.
No timeframe for change is required.
The final score is a sum of the number items marked “Yes, A change”.
Appendix 4. Commonly used cognitive assessments/screening tools
TEST Cochrane DTA review in process
Mini-mental state examination (MMSE) YES
GPcog YES
Minicog YES
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(Continued)
Memory Impairment Screen (MIS) Still available
Abbreviated mental testing Still available
Clock drawing tests (CDT) Still available
Montreal Cognitive Assessment (MoCA) YES
IQCODE (informant interview) YES
For each test, the planned review will encompass diagnostic test accuracy in community; primary and secondary care settings.
Appendix 5. Sources searched and search strategies
Source Search strategy Hits retrieved
ALOIS DTA
[Date of most recent search: 7 June 2018]
AD8 OR AD-8 OR “AD 8” OR
“Alzheimer’s Disease eight question screen”
See Appendix 6 for the searches run to pop-
ulate the ALOIS register
May 2014: 15
May 2017: 3
June 2018: 0
MEDLINE In-process and other non-
indexed citations and MEDLINE 1950-
present (Ovid SP)
[Date of most recent search: 7 June 2018]
1. AD8.ti,ab.
2. “informant questionnaire on cognitive
decline”.ti,ab.
3. “Alzheimer’s Disease eight question
screen”.ti,ab.
4. “AD 8”.ti,ab.
5. (“informant* questionnair*” adj3 (de-
ment* or screening)).ti,ab
6. (“screening test*” adj2 (dement* or
alzheimer*)).ti,ab.
7. or/1-6
May 2014: 300
May 2017: 54
June 2018: 48
EMBASE
1974-2018 June 6 (Ovid SP)
[Date of most recent search: 7 June 2018]
1. AD8.ti,ab.
2. “informant questionnaire on cognitive
decline”.ti,ab.
3. “Alzheimer’s Disease eight question
screen”.ti,ab.
4. “AD 8”.ti,ab.
5. (“informant* questionnair*” adj3 (de-
ment* or screening)).ti,ab
6. (“screening test*” adj2 (dement* or
alzheimer*)).ti,ab.
7. or/1-6
May 2014: 487
May 2017: 75
June 2018: 58
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(Continued)
PSYCINFO
1806-June week 1 2018 (Ovid SP)
[Date of most recent search: 7 June 2018]
1. AD8.ti,ab.
2. “informant questionnaire on cognitive
decline”.ti,ab.
3. “Alzheimer’s Disease eight question
screen”.ti,ab.
4. “AD 8”.ti,ab.
5. (“informant* questionnair*” adj3 (de-
ment* or screening)).ti,ab
6. (“screening test*” adj2 (dement* or
alzheimer*)).ti,ab.
7. or/1-6
May 2014: 159
May 2017: 66
June 2018: 31
CINAHL (EBSCOhost)
[Date of most recent search: 7 June 2018]
S13 S1 OR S12
S12 S10 AND S11
S11 TX informer* OR informant*
S10 S5 AND S9
S9 S6 OR S7 OR S8
S8 (MM “Alzheimer’s Disease/DI”)
S7 (MM “Dementia”) OR (MM “Delir-
ium, Dementia, Amnestic, Cognitive Dis-
orders”)
S6TXdement*ORalzheimer*ORcognit*
S5 S2 OR S3 OR S4
S4 TX (cognit* OR memory) n3 screen*
S3 TX “neuropsychological test*” OR
“neurocog* test*” OR “cog* test*”
S2 TX “neuropsychological assess*” OR
“neurocog* assess*” OR “cog* assess*”
S1 TX AD8
May 2014: 219
May 2017: 49
June 2018: 29
Biosis previews 1926 to present (ISI Web
of Science)
[Date of most recent search: 7 June 2018]
(AD8 or “informant questionnaire on cog-
nitive decline” or “Alzheimer’s Disease
eight question screen” or “AD 8” or (“in-
formant* questionnair*” and dement*) or
(“screening test*” and dement*) or (“infor-
mant* questionnair*” and alzheimer*) or
(“screening test*” and alzheimer*))
May 2014: 710
May 2017: 104
June 2018: 93
Web of Science Core Collection (1945-
present) (ISI Web of Science)
[Date of most recent search: 7 June 2018]
(AD8 or “informant questionnaire on cog-
nitive decline” or “Alzheimer’s Disease
eight question screen” or “AD 8” or (“in-
formant* questionnair*” and dement*) or
(“screening test*” and dement*) or (“infor-
mant* questionnair*” and alzheimer*) or
(“screening test*” and alzheimer*))
May 2014: 869
May 2017: 188
June 2018: 101
LILACS (BIREME)
[Date of most recent search: 7 June 2018]
(AD8 or “informant questionnaire on cog-
nitive decline” or “Alzheimer’s Disease
eight question screen” or “AD 8”
May 2014: 1
May 2017: 1
June 2018: 1
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(Continued)
MEDION
database (Meta-analyses van Diagnostisch
Onderzoek www.mediondatabase.nl);
DARE (Database of Abstracts of Reviews of
Effects) and HTA Database (Health Tech-
nology Assessments Database), both The
Cochrane Library;
ARIF database (Aggressive Research Intel-
ligence Facility; www.arif.bham.ac.uk).
[Date of most recent search: 7 June 2018]
(AD8 or “informant questionnaire on cog-
nitive decline” or “Alzheimer’s Disease
eight question screen” or “AD 8”
June 2018: 0
TOTAL before de-duplication May 2014: 2760
May 2017: 540
June 2018: 361
TOTAL: 3661
TOTAL after de-duplication and first-assessment by CDCIG information specialist
based on titles and abstracts
May 2014: 447
May 2017: 162
June 2018: 5
TOTAL: 614
Appendix 6. Search strategy (MEDLINE Ovid SP) run for specialised register (ALOIS)
Search narrative: The searches detailed above are very simple, essentially single concept strategies based on the index test (AD-8). This
is a sensitive approach to take. More complex and developed searches are run each month for the dementia group.
Every month the following strategy is run in Medline (via Ovid SP). The results are screened based on a reading of title and abstract.
The full texts (where there is one) are then obtained and a few key details about each study are extracted including Index test/s and
details of population and setting. For this review it was expected that most studies would be identified through a search of multiple
sources based on one concept (the index test in question). However, we felt it was worth also searching ALOIS for any studies which
had evaluated the accuracy of AD-8 but had not referred to it in the bibliographic details of the reference.
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MEDLINE In-process and other non-indexed citations and
MEDLINE 1950-present (Ovid SP)
1. “word recall”.ti,ab.
2. “7-minute screen”.ti,ab.
3. “6 item cognitive impairment test”.ti,ab.
4. “6 CIT”.ti,ab.
5. “AB cognitive screen”.ti,ab.
6. “abbreviated mental test”.ti,ab.
7. “ADAS-cog”.ti,ab.
8. AD8.ti,ab.
9. “inform* interview”.ti,ab.
10. “animal fluency test”.ti,ab.
11. “brief alzheimer* screen”.ti,ab.
12. “brief cognitive scale”.ti,ab.
13. “clinical dementia rating scale”.ti,ab.
14. “clinical dementia test”.ti,ab.
15. “community screening interview for dementia”.ti,ab.
16. “cognitive abilities screening instrument”.ti,ab.
17. “cognitive assessment screening test”.ti,ab.
18. “cognitive capacity screening examination”.ti,ab.
19. “clock drawing test”.ti,ab.
20. “deterioration cognitive observee”.ti,ab.
21. “Dem Tect”.ti,ab.
22. “fuld object memory evaluation”.ti,ab.
23. “IQCODE”.ti,ab.
24. “mattis dementia rating scale”.ti,ab.
25. “memory impairment screen”.ti,ab.
26. “minnesota cognitive acuity screen”.ti,ab.
27. “mini-cog”.ti,ab.
28. “mini-mental state exam*”.ti,ab.
29. “mmse”.ti,ab.
30. “modified mini-mental state exam”.ti,ab.
31. “3MS”.ti,ab.
32. “neurobehavioural cognitive status exam*”.ti,ab.
33. “cognistat”.ti,ab.
34. “quick cognitive screening test”.ti,ab.
35. “QCST”.ti,ab.
36. “rapid dementia screening test”.ti,ab.
37. “RDST”.ti,ab.
38. “repeatable battery for the assessment of neuropsychological
status”.ti,ab
39. “RBANS”.ti,ab.
40. “rowland universal dementia assessment scale”.ti,ab.
41. “rudas”.ti,ab.
42. “self-administered gerocognitive exam*”.ti,ab.
43. (“self-administered” and “SAGE”).ti,ab.
44. “self-administered computerized screening test for dementia”.
ti,ab
45. “short and sweet screening instrument”.ti,ab.
46. “sassi”.ti,ab.
47. “short cognitive performance test”.ti,ab.
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48. “syndrome kurztest”.ti,ab.
49. “six item screener”.ti,ab.
50. “short memory questionnaire”.ti,ab.
51. (“short memory questionnaire” and “SMQ”).ti,ab.
52. “short orientation memory concentration test”.ti,ab.
53. “s-omc”.ti,ab.
54. “short blessed test”.ti,ab.
55. “short portable mental status questionnaire”.ti,ab.
56. “spmsq”.ti,ab.
57. “short test of mental status”.ti,ab.
58. “telephone interview of cognitive status modified”.ti,ab
59. “tics-m”.ti,ab.
60. “trail making test”.ti,ab.
61. “verbal fluency categories”.ti,ab.
62. “WORLD test”.ti,ab.
63. “general practitioner assessment of cognition”.ti,ab.
64. “GPCOG”.ti,ab.
65. “Hopkins verbal learning test”.ti,ab.
66. “HVLT”.ti,ab.
67. “time and change test”.ti,ab.
68. “modified world test”.ti,ab.
69. “symptoms of dementia screener”.ti,ab.
70. “dementia questionnaire”.ti,ab.
71. “7MS”.ti,ab.
72. (“concord informant dementia scale” or CIDS).ti,ab.
73. (SAPH or “dementia screening and perceived harm*”).ti,ab
74. or/1-73
75. exp Dementia/
76. Delirium, Dementia, Amnestic, Cognitive Disorders/ OR
Cognition Disorders/ OR Memory Disorders/
77. dement*.ti,ab.
78. alzheimer*.ti,ab.
79. AD.ti,ab.
80. (“lewy bod*” or DLB or LBD).ti,ab.
81. “cognit* impair*”.ti,ab.
82. (cognit* adj4 (disorder* or declin* or fail* or function*)).ti,ab
83. (memory adj3 (complain* or declin* or function*)).ti,ab.
84. or/75-83
85. exp “sensitivity and specificity”/
86. “reproducibility of results”/
87. (predict* adj3 (dement* or AD or alzheimer*)).ti,ab.
88. (identif* adj3 (dement* or AD or alzheimer*)).ti,ab.
89. (discriminat* adj3 (dement* or AD or alzheimer*)).ti,ab.
90. (distinguish* adj3 (dement* or AD or alzheimer*)).ti,ab.
91. (differenti* adj3 (dement* or AD or alzheimer*)).ti,ab.
92. diagnos*.ti.
93. di.fs.
94. sensitivit*.ab.
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95. specificit*.ab.
96. (ROC or “receiver operat*”).ab.
97. Area under curve/
98. (“Area under curve” or AUC).ab.
99. (detect* adj3 (dement* or AD or alzheimer*)).ti,ab.
100. sROC.ab.
101. accura*.ti,ab.
102. (likelihood adj3 (ratio* or function*)).ab.
103. (conver* adj3 (dement* or AD or alzheimer*)).ti,ab.
104. ((true or false) adj3 (positive* or negative*)).ab.
105. ((positive* or negative* or false or true) adj3 rate*).ti,ab
106. or/85-105
107. exp dementia/di OR Delirium, Dementia, Amnestic, Cog-
nitive Disorders/di
108. Cognition Disorders/di
109. Memory Disorders/di
110. or/107-109
111. *Neuropsychological Tests/
112. *Questionnaires/
113. Geriatric Assessment/mt
114. *Geriatric Assessment/
115. Neuropsychological Tests/mt, st
116. “neuropsychological test*”.ti,ab.
117. (neuropsychological adj (assess* or evaluat* or test*)).ti,ab
118. (neuropsychological adj (assess* or evaluat* or test* or exam*
or battery)).ti,ab
119. Self report/
120. self-assessment/ or diagnostic self evaluation/
121. Mass Screening/
122. early diagnosis/
123. or/111-122
124. 74 or 123
125. 110 and 124
126. 74 or 123
127. 84 and 106 and 126
128. 74 and 106
129. 125 or 127 or 128
130. (animals not (humans and animals)).sh.
131. 129 not 130
The concepts for this are:
A Specific neuropsychological tests
B General terms (both free text and MeSH) for tests/testing/
screening
COutcome: dementia diagnosis (unfocusedMeSHwith diagnos-
tic sub-headings)
D Condition of interest: Dementia (general dementia terms both
free text and MeSH - exploded and unfocused)
EMethodological filter: not used to limit all search
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The concept combinations are:
1. (A OR B) AND C
2. (A OR B) AND D AND E
3. A AND E
Appendix 7. Example translation proforma
Study ID
Population and setting Which of the following does the study best fall into?
a) Asymptomatic community
b) Symptomatic community
c) Asymptomatic primary
d) Symptomatic primary
e) Secondary care (memory focus)
f ) Secondary care (non-memory focus)
g) Mixed
h) None of the above
If h) please describe the setting population:
Study design: Participants a) How were they sampled?
a. Randomly (cluster sampling)
b. Consecutively
c. Not reported
d. Other (please describe)
b) Was a case control design avoided?
a. Yes
b. No
c. Not sure (please elaborate if possible)
c) Please describe any exclusion criteria stated in the paper
Participant characteristics Of the participants included in the study:
a) What was their mean age? Please say Not reported if this is not
reported in the paper:
b)What percentage of the participants were female? Please say Not
reported if this is not reported in the paper or easy to calculate from
the information given:
c) What was the average level of education of the participants?
Please just state whatever information is in the paper regarding the
educational level of the participants
What was the mean AD-8 score? Please say Not reported if this is not
reported in the paper or easy to calculate from the information given
d) If the study concerns MCI “progression” howwasMCI defined?
Give classification criteria eg Peterson, say not reported if this is not
described
e)How many participants were included in the study?
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(Continued)
Target condition + reference standard [Target condition should be dementia. It may be a form of dementia
such as Alzheimer’s. The reference standard is likely to be DSM-III or
DSM-IV: just note down whatever diagnostic criteria they appeared
to use to diagnose dementia.]
a) What reference standard has been used?
b) Did all the participants have the reference standard?
a. Yes
b. No. Please describe how those who did have the reference standard
had been selected and state how many had it (if this is not reported
please say Not reported)
Please provide a brief description/translation of how the reference
standard was carried out and by whom:
[If it’s not AD-8 then it’s out!]
Was this a translated version of the AD-8 that was used? If the AD-
8 used was translated or modified in any way, is there any evidence that
the version used had been validated, or was this study the validation
of that version?
Who conducted the Index test?
a) Trained specialist
b) Trained non-specialist
Please provide a brief description/translation of how the Index test
was carried out:
Duration of time between index test and reference standard [please put Not reported if this information is not provided - it quite
often isn’t]
a)What was the time period between the conduct of the tests?
b) Are there any participants who appear to be unaccounted for?
(you can Unsure if you are not sure about this)
Results Is the sensitivity and specificity of the AD-8 against the reference
standard reported or extractable do you think?
If yes, what cut point on the AD-8 has been used (there may be several
cut points used - please list them all. It might be best to give a fairly
detailed translation of the results section because we will need to as-
certain which score on the AD-8 indicates normality)
If you are able to extract the data, please do so. Ideally we would
like the four numbers for each cutpoint reported: True Positive, True
Negative, False Positive, False Negative
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Appendix 8. Assessment of methodological quality table QUADAS-2 tool
DOMAIN PATIENT
SELECTION
INDEX TEST REFERENCE
STANDARD
FLOW AND TIMING
Description Describe methods of pa-
tient selection: Describe
included patients (prior
testing, presentation, in-
tended use of index test
and setting):
Describe the index test
and how it was con-
ducted and interpreted:
Describe the reference
standard and how it
was conducted and in-
terpreted:
Describe any patients
who did not receive the
index test(s) and/or ref-
erence standard or who
were excluded from the
2x2 table (refer to flow
diagram): Describe the
time interval and any in-
terventions between in-
dex test(s) and reference
standard:
Signalling questions
(yes/no/unclear)
Was a consecutive or ran-
dom sample of patients
enrolled?
Were the index test re-
sults interpreted without
knowledge of the results
of the reference stan-
dard?
Is the reference standard
likely to correctly classify
the target condition?
Was there an appropri-
ate interval between in-
dex test(s) and reference
standard?
Was a case-control de-
sign avoided?
If a threshold was used,
was it pre-specified?
Were the reference stan-
dard results interpreted
without knowledge of
the results of the index
test?
Did all patients receive a
reference standard?
Did the study avoid in-
appropriate exclusions?
Did all patients receive
the same reference stan-
dard?
Were all patients in-
cluded in the analysis?
Risk of bias: High/low/
unclear
Could the selection of
patients have introduced
bias?
Could the conduct or in-
terpretation of the in-
dex test have introduced
bias?
Could the reference stan-
dard, its conduct, or its
interpretation have in-
troduced bias?
Could the patient flow
have introduced bias?
Concerns regarding
applicability: High/low/
unclear
Are there concerns that
the included patients do
not match the review
question?
Are there concerns that
the index test, its con-
duct, or interpretation
differ from the review
question?
Are there concerns that
the target condition as
defined by the reference
standard does not match
the review question?
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Appendix 9. Anchoring statements for quality assessment of AD-8 diagnostic studies
We provide some core anchoring statements for quality assessment of diagnostic test accuracy reviews of AD-8 in dementia. These
statements are designed for use with the QUADAS-2 tool and were derived during a two-day, multidisciplinary focus group (Davis
2013).
During the focus group and the piloting/validation of this guidance, it was clear that certain issues were key to assessing quality, while
other issues were important to record but less important for assessing overall quality. To assist, we describe a system wherein certain
items can dominate. For these dominant items, if scored “high risk” then that section of the QUADAS-2 results table is likely to be
scored as high risk of bias regardless of other scores. For example, in dementia diagnostic test accuracy studies, ensuring that clinicians
performing dementia assessment are blinded to results of index test is fundamental. If this blinding was not present then the item on
reference standard should be scored “high risk of bias”, regardless of the other contributory elements.
We have detailed how QUADAS-2 has been operationalised for use with dementia reference standard studies below. In these descriptors
dominant items are labelled as “high risk of bias for total section regardless of other items”.
In assessing individual items, the score of unclear should only be given if there is genuine uncertainty. In these situations review authors
will contact the relevant study teams for additional information.
Anchoring statements to assist with assessment for risk of bias
Selection
Was a case-control or similar design avoided?
Designs similar to case-control that may introduce bias are those designs where the study team deliberately increase or decrease the
proportion with the target condition. For example, a population study may be enriched with extra dementia patients from a secondary
care setting. Such studies will be automatically labelled high risk of bias and this will be assessed as a potential source of heterogeneity.
If case-control is used then grading will be high risk of bias for total section regardless of other items (in fact case-control studies will
not be included in this review).
Was the sampling method appropriate?
Where sampling is used, the designs least likely to cause bias are consecutive sampling or random sampling. Sampling that is based on
volunteers or selecting participants from a clinic or research resource is prone to bias.
Are exclusion criteria described and appropriate?
The study will be automatically graded as unclear if exclusions are not detailed (pending contact with study authors). Where exclusions
are detailed, the study will be graded as low risk of bias if exclusions are felt to be appropriate by the review authors. Certain exclusions
common to many studies of dementia are: medical instability; terminal disease; alcohol/substance misuse; concomitant psychiatric
diagnosis; other neurodegenerative condition.
Post hoc exclusions will be labelled high risk of bias for total section regardless of other items.
Index Test
Was AD-8 assessment performed without knowledge of clinical dementia diagnosis?
Terms such as “blinded” or “independently and without knowledge of” are sufficient and full details of the blinding procedure are not
required. This item may be scored as low risk of bias if explicitly described or if there is a clear temporal pattern to order of testing that
precludes the need for formal blinding i.e. all AD-8 assessments performed before dementia assessment.
If there is no attempt at blinding grading will be high risk of bias for total section regardless of other items.
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Were AD-8 thresholds prespecified?
For scales there is often a reference point (in units or categories) above which participants are classified as “test positive”; this may be
referred to as threshold; clinical cut-off or dichotomisation point. A study is classified high risk of bias if the authors define the optimal
cut-off post-hoc based on their own study data. Certain papers may use an alternative methodology for analysis that does not use
thresholds and these papers should be classified as low risk of bias.
Were sufficient data on AD-8 application given for the test to be repeated in an independent study?
Particular points of interest for AD-8 include method of administration (for example, self-completed questionnaire versus direct
questioning interview); nature of informant; language of assessment. If a novel form of AD-8 is used, details of the scale should be
included or a reference given to an appropriate descriptive text. Where AD-8 is used in a novel manner, for example, a translated
questionnaire, there should be evidence of validation work.
Reference Standard
Is the assessment used for clinical diagnosis of dementia acceptable?
Commonly used international criteria to assist with clinical diagnosis of dementia include those detailed in DSM-IV and ICD-10.
Criteria specific to dementia subtypes include but are not limited to NINCDS-ADRDA criteria for Alzheimer’s dementia; McKeith
criteria for Lewy Body dementia; Lund criteria for frontotemporal dementias; and the NINDS-AIREN criteria for vascular dementia.
We included use of the Clinical Dementia Rating (CDR) assessment as an accepetd method of dementai diagnosis. Where the criteria
used for assessment are not familiar to the review authors or the Cochrane Dementia and Cognitive Improvement Group this item
should be classified as high risk of bias.
Was clinical assessment for dementia performed without knowledge of AD-8?
Terms such as “blinded” or “independent” are sufficient and full details of the blinding procedure are not required. This may be scored
as low risk of bias if explicitly described or if there is a clear temporal pattern to order of testing, i.e. all dementia assessments performed
before AD-8 testing.
Informant rating scales and direct cognitive tests present certain problems. It is accepted that informant interview and cognitive testing
is a usual component of clinical assessment for dementia, however, specific use of the scale under review in the clinical dementia
assessment should be scored as high risk of bias. We have prespecified that dementia diagnosis that explicitly uses AD-8 will be classified
as high risk of bias for total section regardless of other items.
Were sufficient data on dementia assessment method given for the assessment to be repeated in an independent study?
The criteria used for clinical assessment are discussed in another item. Particular points of interest for dementia assessment include
the background of the assessor, training/expertise of the assessor; additional information available to inform diagnosis (neuroimaging;
neuropsychological testing).
Flow
Was there an appropriate interval between AD-8 and clinical dementia assessment?
For a cross-sectional study design, there is potential for change between assessments. The ideal would be same day assessment but this
is not always feasible. We have set an arbitrary maximum interval of one month between tests, although this may be revised depending
on the test and the stability of the condition of interest.
For a study looking at delayed verification there is no agreement on how long the interval should be between index test and first/last
assessment for dementia. An interval of less than six months is unlikely to be sufficient time for progression.
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Did all get the same assessment for dementia regardless of AD-8 result?
Theremay be scenarios where only those who score “test positive” on AD-8 have amore detailed assessment.Where dementia assessment
(or other reference standard) differs depending on the AD-8 result this should be classified as high risk of bias.
Were all who received AD-8 assessment included in the final analysis?
If the study has drop outs these should be accounted for; a maximum proportion of drop outs to remain low risk of bias has been
specified as 20%.
Were missing AD-8 results or un-interpretable AD-8 results reported?
Where missing results are reported if there is substantial attrition (we have set an arbitrary value of 50% missing data) this should be
scored as high risk of bias for total section regardless of other items.
Applicability
Were those included representative of the general population of interest?
Those included should match the intended population as described in the review question. If not already specified in the review
inclusion criteria, setting will be particularly important - the review authors should consider population in terms of symptoms; pre-
testing; potential disease prevalence. Studies that use very selected groups or subgroups will be classified as poor applicability.
Was AD-8 performed consistently and in a manner similar to its use in clinical practice?
AD-8 studies will be judged against the original description of its use.
Was clinical diagnosis of dementia (or other reference standard) made in a manner similar to current clinical practice?
For many reviews, inclusion criteria and assessment for risk of bias will already have assessed the dementia diagnosis. For certain
reviews an applicability statement relating to reference standard may not be applicable. There is the possibility that a form of dementia
assessment, although valid, may diagnose a far larger proportion with disease than would be seen in usual clinical practice. In this
instance the item should be rated poor applicability.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The title of the review has been changed from “AD-8 for diagnosis of dementia across a variety of healthcare settings” to “AD-8 for
detection of dementia across a variety of healthcare settings”. This change is consistent with the use of AD-8 described in the review
- for research and clinical practice - as a tool to identify those who may benefit from diagnostic assessment, rather than as a single
diagnostic test.
The secondary objectives text has been altered between the protocol and the review, to be consistent with the other test accuracy reviews
of informant tools. The review specifies in the secondary objectives that the diagnostic accuracy has been described at various predefined
threshold scores. The review does not describe the accuracy of AD-8 for early detection of cognitive problems, where a later diagnosis
of dementia is made (delayed verification diagnosis) as no studies using this methodology were identified in the search.
The modest number of papers limited the sensitivity and subgroup analyses that we could perform. For example, we had planned on
having summary analyses for each individual healthcare setting as primary analysis, with an analysis across all healthcare settings as a
secondary analysis. Numbers of papers only allowed a summary analysis across all settings at a cut-off score of two.
We had planned on assessing reporting quality using STARD. We have performed this but have not incorporated these data into the
review. We note that reporting guidance for all test accuracy and for studies with a dementia outcome has evolved from the original
iteration of STARD.
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